Document:

EXHIBIT 10.38

===============================================================================

                          EXCLUSIVE MARKETING AGREEMENT

                                  BY AND AMONG

                                 OSTEOTECH, INC.

                                     LIFENET

                            DEPUY ORTHOPAEDICS, INC.

                                       AND

                               DEPUY ACROMED, INC.

                          DATED AS OF DECEMBER 13, 2002

================================================================================

***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-13
<PAGE>

                                TABLE OF CONTENTS

                                                                            PAGE
                                                                            ----
Section 1         DEFINITIONS; CONSTRUCTION....................................1

     1.1      "510(k) Premarket Notification"..................................1
     1.2      "AAA"............................................................2
     1.3      "AATB"...........................................................2
     1.4      "Adverse Reaction Report"........................................2
     1.5      "Affiliate"......................................................2
     1.6      "Agreement"......................................................2
     1.7      "Allograft Bone Tissue"..........................................2
     1.8      "Annual End User Fees"...........................................2
     1.9      "Audit Report"...................................................2
     1.10     "Auditor"........................................................2
     1.11     "BMPs"...........................................................2
     1.12     "Bio-Implant Allografts".........................................2
     1.13     "Business Day"...................................................2
     1.14     "Carrier Allograft"..............................................2
     1.15     "Carry-Over Period"..............................................2
     1.16     "Confidential Information".......................................2
     1.17     "Contract Year"..................................................3
     1.18     "Corrective Payment".............................................3
     1.19     "Customers"......................................................3
     1.20     "DBM Carrier Products"...........................................3
     1.21     "DBM Notice of Sale".............................................3
     1.22     "DBM Promoting Affiliates".......................................4
     1.23     "DePuy"..........................................................4
     1.24     "DePuy AcroMed"..................................................4
     1.25     "DePuy Comment Period"...........................................4
     1.26     "DePuy Orthopaedics".............................................4
     1.27     "DePuy Service Fee"..............................................4
     1.28     "Effective Date".................................................5
     1.29     "End User Fee"...................................................5
     1.30     "FDA"............................................................5
     1.31     "FDA Carry-Over Period"..........................................5
     1.32     "Field"..........................................................5
     1.33     "Final Packaging"................................................5
     1.34     "First Right"....................................................5

                                      E-14
<PAGE>

     1.35     "Force Majeure"..................................................5
     1.36     "Initial Forecast"...............................................5
     1.37     "Initial Packaging"..............................................5
     1.38     "Inventory Carrying Costs".......................................6
     1.39     "Inventory Supply"...............................................6
     1.40     "Invoice Date"...................................................6
     1.41     "Laws and Rules".................................................6
     1.42     "LifeNet"........................................................6
     1.43     "LifeNet Fee"....................................................6
     1.44     "LifeNet Patents"................................................6
     1.45     "LifeNet Technology".............................................6
     1.46     "LifeNet Traditional and Non-Carrier Based Tissues"..............6
     1.47     "Losses".........................................................6
     1.48     "Materially Burdensome Condition"................................7
     1.49     ***..............................................................7
     1.50     "NOTA"...........................................................7
     1.51     "Osteotech"......................................................7
     1.52     "Osteotech Comment Period".......................................7
     1.53     "Osteotech Patents"..............................................7
     1.54     "Osteotech Service Fee"..........................................7
     1.55     "Osteotech Suggested End User Fees"..............................7
     1.56     "Party"..........................................................7
     1.57     "Person".........................................................7
     1.58     "Pre-Existing Distribution Agreement"............................7
     1.59     "Premarket Approval (PMA)".......................................8
     1.60     "Primary Agreement"..............................................8
     1.61     "Product"........................................................8
     1.62     "Product Complaint"..............................................8
     1.63     "Product Development Payment"....................................8
     1.64     "Promotional Budget".............................................8
     1.65     "Promotional Materials"..........................................8
     1.66     "Reasonable Efforts".............................................8
     1.67     "Remedy Period"..................................................9
     1.68     "Required Characteristics".......................................9
     1.69     "Section 7.1 Report".............................................9

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-15
<PAGE>

     1.70     "Section 7.2 Report".............................................9
     1.71     "Targeted Inventory Level".......................................9
     1.72     "Territory"......................................................9
     1.73     "Tissue Priority Guidelines".....................................9
     1.74     "Trademarks"....................................................10
     1.75     Construction....................................................10

Section 2         PRIMARY AGREEMENT OBLIGATIONS...............................10

     2.1      Supply of Allograft Bone Tissue by LifeNet......................10
     2.2      Processing of Allograft Bone Tissue by Osteotech................11
     2.3      Packaging and Delivery of the Product...........................11
     2.4      License of LifeNet Technology to Osteotech......................11
     2.5      License of Osteotech Patents to LifeNet.........................11
     2.6      Covenant Not to Sue.............................................11
     2.7      Determination of Tissue Providers...............................12
     2.8      In the Event of an Insufficient Supply of Tissue................12
     2.9      Determination of Product Types and Amounts......................12
     2.10     ***.............................................................12

Section 3         EXCLUSIVITY OF PROMOTION....................................13

     3.1      Generally.......................................................13
     3.2      Promotional Restrictions on DePuy...............................13
     3.3      Limited Restrictions on LifeNet.................................13
     3.4      Grafton(R) Exclusion............................................14

Section 4         RELATIONSHIP OF PARTIES; BUDGET.............................14

     4.1      Relationship of the Parties.....................................14
     4.2      Promotional Budget..............................................14

Section 5         OBLIGATIONS AND REPRESENTATIONS OF THE PARTIES..............14

     5.1      Regulatory Matters..............................................14
     5.2      LifeNet Obligations.............................................17
     5.3      DePuy Obligations...............................................17
     5.4      Osteotech Obligations...........................................18
     5.5      Representations, Warranties, and Covenants of the Parties.......19
     5.6      DISCLAIMER......................................................21

Section 6         COMPENSATION................................................21

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-16
<PAGE>

     6.1      End User Fees...................................................21
     6.2      Payment of Service Fees.........................................21
     6.3      Compensation and Expenses.......................................23
     6.4      Inventory Supply and Reimbursements.............................24
     6.5      Product Development Payment.....................................32

Section 7         REPORTS, ETC................................................32

     7.1      Monthly Reports.................................................32
     7.2      Quarterly Reports...............................................32
     7.3      Taxes...........................................................32
     7.4      Audit Rights....................................................32

Section 8         INDEMNIFICATION.............................................33

     8.1      Intellectual Property Indemnification by Osteotech..............33
     8.2      Promotional Material Indemnification by Osteotech...............34
     8.3      General Indemnification by Osteotech............................34
     8.4      Intellectual Property Indemnification by LifeNet................34
     8.5      Promotional Material Indemnification by LifeNet.................34
     8.6      General Indemnification by LifeNet..............................34
     8.7      Indemnification by DePuy........................................35
     8.8      Conditions to Indemnifications..................................35
     8.9      Insurance.......................................................36
     8.10     LIMITATION ON LIABILITY.........................................36

Section 9         CONFIDENTIALITY.............................................37

     9.1      Generally.......................................................37
     9.2      Obligations on Termination......................................37

Section 10        TERM........................................................37

     10.1     Generally.......................................................37
     10.2     Termination of Primary Agreement................................38
     10.3     Bankruptcy......................................................38
     10.4     Material Breach of Representations, Warranties, or Covenants....38
     10.5     Infringement....................................................38
     10.6     Invalidity of Osteotech Patents.................................38
     10.7     Recall or Corrective Action.....................................39
     10.8     Premarket Approval (PMA)........................................39
     10.9     Change in Control of Osteotech..................................39
     10.10    Osteotech Relationship with RTI or Medtronic....................40
     10.11    DBM Notice of Sale..............................................40
     10.12    Distribution of Other DBM Carrier Products by DePuy.............40

                                      E-17
<PAGE>

     10.13    Bone Morphogenic Proteins Exclusion.............................40
     10.14    Corrective Payments by DePuy....................................41
     10.15    Osteotech and LifeNet Right to Waive Termination................42
     10.16    Effect of Certain Terminations on DePuy Thresholds..............42
     10.17    Survival........................................................42

Section 11        TRADEMARKS, TRADENAMES, AND PATENTS.........................43

     11.1     Generally.......................................................43
     11.2     Restriction on Use..............................................43
     11.3     Infringement of Trademarks......................................43
     11.4     Infringement of Osteotech Patents...............................43
     11.5     Infringement of LifeNet Patents.................................43
     11.6     Technology or Intellectual Property Developed
                Subsequent to Effective Date..................................44

Section 12        DISPUTE RESOLUTION..........................................44

     12.1     Mediation.......................................................44
     12.2     Arbitration.....................................................45

Section 13        MISCELLANEOUS...............................................46

     13.1     Notice..........................................................46
     13.2     Force Majeure...................................................47
     13.3     Assignment......................................................47
     13.4     Amendment.......................................................47
     13.5     Waiver..........................................................47
     13.6     Remedies........................................................47
     13.7     Severability....................................................48
     13.8     Governing Law...................................................48
     13.9     Publicity.......................................................48
     13.10    Headings........................................................48
     13.11    Entire Agreement................................................48
     13.12    Conflicts with Primary Agreement................................49
     13.13    Fees and Expenses...............................................49
     13.14    Incorporation by Reference......................................49
     13.15    Interpretation..................................................49
     13.16    Counterparty and Facsimile Signatures...........................49

                                      E-18
<PAGE>

                          EXCLUSIVE MARKETING AGREEMENT

            This Exclusive Marketing Agreement (the "AGREEMENT") is made as of
the 13th day of December, 2002, by and among Osteotech, Inc., a tissue bank
accredited by the AATB and a corporation organized and existing under the laws
of the state of Delaware ("OSTEOTECH"), LifeNet, a tissue bank accredited by the
AATB and a not-for-profit corporation organized and existing under the laws of
the Commonwealth of Virginia ("LIFENET"), DePuy Orthopaedics, Inc., a
corporation organized and existing under the laws of Indiana, ("DEPUY
ORTHOPAEDICS") and DePuy AcroMed, Inc., a corporation organized and existing
under the laws of Ohio and an Affiliate of DePuy Orthopaedics ("DEPUY ACROMED",
DePuy Orthopaedics and DePuy AcroMed are together referred to herein as
"DEPUY"), each of Osteotech, LifeNet, DePuy Orthopaedics and DePuy AcroMed being
a "PARTY", and collectively referred to as the "PARTIES". Capitalized terms used
in this Agreement shall have the meanings assigned to them in Section 1 hereof,
unless otherwise defined elsewhere in this Agreement.

            WHEREAS, LifeNet and Osteotech have entered into the Primary
Agreement which, among other things, contemplates that this Agreement will be
entered into; and

            WHEREAS, to enhance the usefulness of, and encourage the use by
hospitals and physicians of bone tissue recovered from human donors (i.e., human
allograft bone tissue), the Parties agree to enter into this Agreement pursuant
to which:

            (a) LifeNet will provide Allograft Bone Tissue to Osteotech for
further processing;

            (b) Osteotech will further process, utilizing its proprietary
technology, the Allograft Bone Tissue (to include demineralization if not
previously performed by LifeNet) and will combine such demineralized Allograft
Bone Tissue with a glycerol-based carrier in order to produce for subsequent
distribution by LifeNet (and its designees) the Products; and

            (c) Osteotech will engage DePuy to promote the Products and will
grant to DePuy the exclusive rights to promote such Products in the Field
throughout the Territory

            WHEREAS, LifeNet processes human allograft bone tissue into forms
suitable for clinical use and promotes and distributes the processed tissue, and
can obtain reasonable payment from tissue recipients (e g hospitals and
physicians) in compliance with NOTA

            NOW, THEREFORE, the Parties hereby agree as follows:

SECTION 1 DEFINITIONS; CONSTRUCTION

      1.1 "510(k) Premarket Notification" shall mean the premarketing
notification submission made to the FDA prior to the marketing of Class I, Class
II, and some Class III devices intended for human use to demonstrate that the
device to be marketed is substantially equivalent to a predicate device (or any
functionally equivalent submission that may hereinafter be promulgated by the
FDA that would be applicable to the Product).

                                      E-19
<PAGE>

      1.2 "AAA" shall mean the American Arbitration Association.

      1.3 "AATB" shall mean the American Association of Tissue Banks.

      1.4 "Adverse Reaction Report" shall mean any communication, whether verbal
or in writing, that conveys an actual or suspected serious injury (an injury
that is reasonably likely to lead to death or permanent disability or which
requires significant medical intervention to treat) or death that is alleged to
be caused by the Product or any component thereof.

      1.5 "Affiliate" shall mean, in respect of any Party or third party, any
Person which is controlled by or is under common control with such Party or
third party, as the case may be. For the purposes of this definition, "control"
shall mean the possession, directly or indirectly, of the power to direct or
cause the direction of the management and policies of such Person, whether
through the ownership of voting securities, by contract or otherwise.

      1.6 "Agreement" shall have the meaning ascribed thereto in the preamble.

      1.7 "Allograft Bone Tissue" shall mean aseptically recovered human
allograft bone tissue***.

      1.8 "Annual End User Fees" shall mean the aggregate amount of End User
Fees invoiced to Customers in connection with the Products for each Contract
Year.

      1.9 "Audit Report" shall mean the report prepared by the Auditor.

      1.10 "Auditor" shall mean an independent accounting firm.

      1.11 "BMPs" shall mean bone morphogenic proteins.

      1.12 "Bio-Implant Allografts" shall mean a line of allograft-based,
structural spinal bio-implants produced by Osteotech pursuant to the terms and
conditions of the Primary Agreement including the tradenames of Graftech (TM)
Anterior Ramp, Graftech(TM) Posterior Ramp, Graftech(TM) Cervical Spacer,
Graftech(TM) Cervical Dowel and Graftech(TM) Cortical Spacers.

      1.13 "Business Day" shall mean any day other than a Saturday or Sunday or
other day on which banks are authorized to be closed in the Commonwealth of
Virginia.

      1.14 "Carrier Allograft" shall mean allograft bone formulations,
prepackaged and distributed within a biocompatible chemical carrier for delivery
of such allograft bone tissue to the surgical site.

      1.15 "Carry-Over Period" shall mean a period of two (2) years from the
date of termination of this Agreement.

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-20
<PAGE>

      1.16 "Confidential Information" means any information, except such
information identified in the last sentence of this Section 1.16, that is
disclosed to any Party by any other Party which is provided in writing (or
reduced to writing promptly after oral disclosure) and marked "confidential."
Consistent with the foregoing, Confidential Information includes: all general
and specific knowledge, experience and information that is confidential and of
value to the Party who possesses it, including without limitation, formulations,
designs, products, processes, supplies, methods of manufacture or processing,
SOPs, cost data, master files; the nature of research and/or development
projects, as well as data relating thereto; marketing, promotional or business
plans; donor data; information related to a Product; the development status of a
Product; Product indications and modes of administration; technical information;
business information, such as reports, records, customer lists, supplier lists,
and marketing, promotional and sales or distribution plans; financial
information such as costs and pricing information, and economic analyses, if
any, conducted with respect to a Product. Notwithstanding the foregoing,
Confidential Information shall not include information: (a) that was previously
known to the recipient or independently developed, in each case, as evidenced by
recipient's written records, (b) that is lawfully obtained by recipient from a
source independent of the disclosing Party, (c) that is now or becomes public
knowledge other than by breach of this Agreement, or (d) that is legally
required to be disclosed under federal or state law, provided that the Party
required to make the disclosure takes reasonable steps, consistent with
protection it would seek for its own Confidential Information, to prevent the
Confidential Information from becoming public and prior to disclosure notifies
the disclosing Party and gives such Party a reasonable opportunity to seek a
protective order.

      1.17 "Contract Year" shall mean the twelve (12) calendar month period
commencing on the Effective Date, and thereafter, each twelve (12) calendar
month period commencing on the calendar day immediately following the last
calendar day of the then preceding Contract Year.

      1.18 "Corrective Payment" shall have the meaning ascribed thereto in
Section 10.14.

      1.19 "Customers" shall mean all hospitals and physicians which place
orders for Products in the Territory.

      1.20 "DBM Carrier Products" shall mean all demineralized, non-load bearing
allograft bone tissue formulations, including without limitation allograft bone
formulations containing other substances or products, which are prepackaged and
distributed within a biocompatible chemical carrier for delivery of such
allograft bone tissue formulations to the surgical site; provided, however, that
an allograft bone tissue formulation which is within a chemical used solely as a
preservative and not a carrier shall not be deemed to be a DBM Carrier Product;
and further provided that autologous materials, such as blood, platelet-rich
plasma, and bone marrow shall not be deemed to be a chemical carrier for
purposes of this definition.

      1.21 "DBM Notice of Sale" shall mean prior written notice provided by
DePuy Orthopaedics under Section 3.2 to Osteotech and LifeNet of its intention
to promote and/or distribute DBM Carrier Products other than Products in the
Territory for the Field.

                                      E-21
<PAGE>

      1.22 "DBM Promoting Affiliates" shall mean those Affiliates of DePuy (or
any of its present or future Affiliates) that markets or sells medical devices
and/or promotes or distributes DBM Carrier Products, in each case, for use in
the Territory for the Field.

      1.23 "DePuy" shall have the meaning ascribed thereto in the preamble.

      1.24 "DePuy AcroMed" shall have the meaning ascribed thereto in the
preamble.

      1.25 "DePuy Comment Period" shall have the meaning ascribed thereto in
Section 5.3.1.

      1.26 "DePuy Orthopaedics" shall have the meaning ascribed thereto in the
preamble.

      1.27 "DePuy Service Fee" shall mean the amount payable by Osteotech to
DePuy, whether paid by Osteotech or by LifeNet on behalf of Osteotech in
accordance with Section 6.2.2, for the promotional services rendered by DePuy in
accordance with this Agreement. The amount of the DePuy Service Fee payable to
DePuy shall be calculated as follows:

                  (a) ***

                  (b) ***

                  (c) An example of how the DePuy Service Fee is calculated is
set forth in EXHIBIT I hereto.

      1.28 "Effective Date" shall mean January 1, 2003.

      1.29 "End User Fee" shall mean, the gross amount invoiced to the Customer
in connection with the Products less any sales or use taxes, tariffs, custom
duties and other government charges, shipping/mailing charges, insurance and
returns.

      1.30 "FDA" shall mean the U.S. Food and Drug Administration.

      1.31 "FDA Carry-Over Period" shall have the meaning ascribed thereto in
Section 6.4.13.

      1.32 "Field" shall mean spine, orthopedic, and trauma.

      1.33 "Final Packaging" shall mean the exterior packaging and labeling of
the Product conforming with the specifications set forth on EXHIBIT H hereto,
including product inserts and tracking materials, and such additional labeling
as is determined by LifeNet to be

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-22
<PAGE>

required by applicable Laws and Rules and placing Product in an appropriate
container for shipping.

      1.34 "First Right" shall mean the right, with priority over any other
Party, to supply, produce, acquire, or negotiate.

      1.35 "Force Majeure" shall mean any cause preventing the performance of
any covenant or obligation to be performed by a Party under this Agreement
beyond the reasonable control of the Party bound by such covenant or obligation,
including fire, explosion, power blackout, earthquake, volcanic action, flood,
hurricane, the elements, strike, embargo, labor disputes, civil or military
authority, war, acts of terrorism, acts of God, acts or omissions of other
carriers, or acts of regulatory or governmental agencies. Changes in economic,
business or competitive conditions or a change in the regulatory status of the
Products are not Force Majeure conditions.

      1.36 "Initial Forecast" shall mean the non-binding forecast of sales for
each Product by product code for the period remaining in the calendar quarter in
which the Effective Date occurs and for each of the four (4) full calendar
quarters thereafter.

      1.37 "Initial Packaging" shall mean the sealed protective pouch provided
by Osteotech that contains a product identity label containing the product code,
donor number and serial number in accordance with the specifications in EXHIBIT
A hereto, which will allow each unit to be tracked to its Customer, as may be
required by applicable Laws and Rules.

      1.38 "Inventory Carrying Costs"***

      1.39 "Inventory Supply" shall mean ***. In the context of a partial
termination, the term "Inventory Supply" shall have the meaning set forth in the
preceding sentence, but only as applied to the Product(s) to which the
termination applies.

      1.40 "Invoice Date" shall mean the date that LifeNet sends an invoice to
the Customer for Products.

      1.41 "Laws and Rules" means all current and future laws, statutes, rules
and regulations of any federal, state or local government or regulatory
authority (e.g., the FDA) or standard setting body (e.g. AATB), including,
without limitation, NOTA, cGTP, the policies and procedures set forth in the
Standards for Tissue Banking and the technical manuals of the AATB.

      1.42 "LifeNet" shall have the meaning ascribed thereto in the preamble.

      1.43 "LifeNet Fee" *** An example of how the LifeNet Fee is calculated is
set forth in EXHIBIT I hereto.

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-23
<PAGE>

      1.44 "LifeNet Patents" shall mean the patents listed in EXHIBIT G hereto
and any extensions and continuations thereof.

      1.45 "LifeNet Technology" shall mean the methods, processes and
formulations covered by any of the claims in the LifeNet Patents listed in
EXHIBIT G hereto and any extensions and continuations thereof.

      1.46 "LifeNet Traditional and Non-Carrier Based Tissues" shall mean human
allograft bone tissue processed for human transplantation that does not
incorporate the use of a patented processing technology not owned or licensed by
LifeNet and (1) in the case of load-bearing tissue, is a single, unitary piece
that is not a composite bone graft composed of two or more bone portions,
including without limitation, iliac crest wedge, cloward dowel, and cortical or
cancellous bone cubes or strips or (2) in the case of non-load-bearing tissue,
does not incorporate pharmaceutically-active agents, carriers, chemical agents,
bio-active agents and/or any other additives or chemicals, including without
limitation, ground and/or particulate cortical and/or cancellous bone tissue.

      1.47 "Losses" shall mean claims, actions or suits, judgments, damages,
litigation costs (including reasonable attorneys' fees and costs), losses,
obligations, or liabilities arising out of third party claims, including without
limitation defending disputes and lawsuits with any regulatory agency, made
against or incurred by an indemnified Party.

      1.48 "Materially Burdensome Condition" shall mean any condition that
materially limits the ability of a Party to operate its business in
substantially the same manner as such business was operated as of the Effective
Date or materially changes the terms of the consideration to be paid in
connection with the transactions contemplated by this Agreement.

      1.49 ***

      1.50 "NOTA" shall mean the National Organ Transplant Act.

      1.51 "Osteotech" shall have the meaning ascribed thereto in the preamble.

      1.52 "Osteotech Comment Period" shall have the meaning ascribed thereto in
Section 5.4.2.

      1.53 "Osteotech Patents" shall mean the patents listed in EXHIBIT F hereto
and any extensions and continuations thereof.

      1.54 "Osteotech Service Fee" shall mean the amount payable by LifeNet to
Osteotech for the services rendered by Osteotech in accordance with this
Agreement, including engaging DePuy for the promotion of the Products, for each
Product unit processed by Osteotech

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-24
<PAGE>

and distributed to Customer(s) by LifeNet. The amount of the Osteotech Service
Fee shall be ***. An example of how the Osteotech Service Fee is calculated is
set forth in EXHIBIT I hereto.

      1.55 "Osteotech Suggested End User Fees" ***

      1.56 "Party" shall have the meaning ascribed thereto in the preamble.

      1.57 "Person" shall mean an individual, or a corporation, a company, a
voluntary association, a partnership, a trust, a joint venture, an
unincorporated organization or any other entity.

      1.58 "Pre-Existing Distribution Agreement" shall mean the marketing,
promotional and distribution agreements which are in effect as of the Effective
Date, entered into by certain of DePuy Orthopaedics' independent distributors
with manufacturers or distributors of DBM Carrier Products in the Territory for
the Field other than the Products.

      1.59 "Premarket Approval (PMA)" shall mean a device marketing application
submitted to the FDA to request approval to market, or to continue marketing of,
a Class III medical device by providing sufficient scientific evidence of the
device's safety and efficacy for its intended use or uses (or any functionally
equivalent submission that may hereinafter be promulgated by the FDA that would
be applicable to the Product).

      1.60 "Primary Agreement" shall mean that certain Primary Agreement, dated
as of January 4, 2002, as amended from time to time, entered into by and between
LifeNet and Osteotech in respect of the processing of certain Carrier Allograft
formulations and bio-implant allograft formulations.

      1.61 "Product" shall mean the Carrier Allograft products described in
EXHIBIT A ***.

      1.62 "Product Complaint" shall mean any communication, whether verbal or
in writing, that conveys actual or suspected problems or difficulties with the
Product or any component thereof, but does not meet the definition of Adverse
Reaction Report.

      1.63 "Product Development Payment"***

      1.64 "Promotional Budget" shall mean the budget prepared and agreed to by
DePuy and LifeNet setting forth the expected expenditures for the Promotional
Materials and activities determined as desirable for promoting the Products for
use in the Field within the Territory. The Promotional Budget may include
without limitation the budget for costs for preclinical studies, laboratory
studies, clinical studies, field aids, training materials, scientific
publications, advertising, dissemination of literature and brochures, exhibition
materials, promotional aids and mailings, and organizing and/or hosting and/or
participating in major

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-25
<PAGE>

national and regional symposia and conventions. The Promotional Budget will
include the budget for the costs of including the Products in DePuy's national
sales meetings and other national or regional training events pursuant to
Section 5.3.2 hereof. ***

      1.65 "Promotional Materials" shall mean, in respect of any Product, all
distribution and promotional materials related to such Product designed and
prepared by LifeNet in consultation with DePuy prior to or during the term of
this Agreement with the assistance and approval of all three Parties in
accordance with Sections 5.3.1 and 5.4.2.

      1.66 "Reasonable Efforts" shall mean those efforts that would be made by a
reasonably prudent business person acting in good faith in the exercise of
reasonable commercial judgment. In the context of a recall, "Reasonable Efforts"
shall mean, as to a Party, an undertaking by such Party to perform or satisfy an
obligation or duty or otherwise act in the manner that a person desirous of
achieving a result would act in similar circumstances to ensure that such result
is achieved as expeditiously as possible; provided, however, that such Party
shall not be required to agree to any Materially Burdensome Condition.

      1.67 "Remedy Period" shall have the meaning ascribed thereto in Section
10.12.

      1.68 "Required Characteristics" shall have the meaning ascribed thereto in
EXHIBIT A hereto.

      1.69 "Section 7.1 Report" shall mean a report, electronic and printed,
created by LifeNet that includes at least each of the following as they apply to
the calendar month reported: (i) a list of each account (using random,
alphanumerical identification of each Customer) that has placed orders for
Products during such calendar month with the End User Fees invoiced for such
Products; (ii) a list of each account (using random, alphanumerical
identification of each Customer) to which Products have been invoiced during
such calendar month; (iii) disposition of all orders for Products placed during
such calendar month; and (iv) all outstanding orders for Products. The Section
7.1 Report submitted to DePuy will contain additional information as reasonably
requested by DePuy, including Customer name and location.

      1.70 "Section 7.2 Report" shall mean the written report created by DePuy
and certified by an applicable officer of DePuy AcroMed or DePuy Orthopaedics,
that (i) specifies whether DePuy and its DBM Promoting Affiliates complied with
the twenty-five per cent (25%) limit set forth in Section 10.12 during the
applicable calendar quarter, and, (ii) in the event DePuy and its DBM Promoting
Affiliates exceeded such limit, specifies the aggregate dollar amount invoiced
by product for DBM Carrier Products promoted by DePuy and its DBM Promoting
Affiliates during the applicable calendar quarter.

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-26
<PAGE>

      1.71 "Targeted Inventory Level" shall mean a finished goods inventory of
Products targeted *** contained in the rolling forecasts of sales provided by
DePuy pursuant to Section 5.3.5 hereof.

      1.72 "Territory" shall mean the 50 states comprising the United States of
America, the District of Columbia, and Puerto Rico; provided that if LifeNet and
Osteotech agree to distribute Products in Canada, they shall so inform DePuy in
writing at least ninety (90) calendar days prior to commencing such distribution
and Canada shall be included in the definition of Territory commencing at the
time such notice is given to DePuy.

      1.73 "Tissue Priority Guidelines" ***

      1.74 "Trademarks" shall mean all trademarks, tradenames, brand names,
logos and designs (whether or not registered) of a Party used during the term of
this Agreement by a Party in connection with the promotion of a Product. The
Trademarks determined as of the Effective Date are listed in EXHIBIT D hereto.

      1.75 Construction. In this Agreement the singular includes the plural and
the plural the singular; references to statutes or regulations are to be
construed as including all statutory or regulatory provisions consolidating,
amending or replacing the statute or regulation referred to; references to
"writing" including printing, typing, lithography and other means of reproducing
words in a tangible visible form; references to articles, section (or
subdivisions of sections), exhibits, annexes or schedules are to this Agreement
unless otherwise indicated; references to agreements and other contractual
instruments shall be deemed to include all schedules and exhibits to such
agreement and all subsequent amendments and other modifications to such
agreements and contractual instruments, but only to the extent such amendments
and other modifications are permitted by the terms of this Agreement, unless
otherwise indicated; and references to persons or entities include their
respective permitted successors and assigns and, in the case of any governmental
entity, governmental entities succeeding to their respective functions and
capacities.

SECTION 2 PRIMARY AGREEMENT OBLIGATIONS

      2.1 Supply of Allograft Bone Tissue by LifeNet. LifeNet will provide
either directly or indirectly through one of its suppliers (as selected by
LifeNet after providing Osteotech and DePuy with notice of the intended supplier
and a reasonable opportunity to lodge a non-binding objection to the use of
tissue provided by such supplier) in accordance with this Agreement, the Primary
Agreement, applicable Laws and Rules, and LifeNet's internal procedures which
implement such Laws and Rules, Allograft Bone Tissue to Osteotech for performing
services in accordance with the terms of this Agreement. LifeNet will maintain
or cause to be maintained in accordance with applicable Laws and Rules all donor
screening and suitability records.

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-27
<PAGE>

      2.2 Processing of Allograft Bone Tissue by Osteotech. Osteotech will
process in accordance with this Agreement, the Primary Agreement, applicable
Laws and Rules, and Osteotech's internal procedures which implement such Laws
and Rules, the Allograft Bone Tissue received from LifeNet into the Product
meeting the specifications set forth on EXHIBIT A. Osteotech shall not use the
Allograft Bone Tissue received from LifeNet (or its designees) for any other
purposes. Osteotech will maintain in accordance with applicable Laws and Rules
all required records including Product design and processing records.

      2.3 Packaging and Delivery of the Product

            2.3.1 Initial Packaging by Osteotech. Prior to supplying the Product
to LifeNet, Osteotech will (1) certify the Product for sterility and expiration
date and (2) insert the Product into the Initial Packaging. The Initial
Packaging developed and used by Osteotech must: be acceptable to LifeNet and
comply with applicable Laws and Rules.

            2.3.2 Delivery of Product by Osteotech to LifeNet. Osteotech will
deliver Product complying with the certification and packaging requirements in
Section 2.3.1 to LifeNet or its designee(s), as directed by LifeNet.

            2.3.3 Final Packaging by LifeNet; Notice of Initial Packaging
Defects. On receipt of the Product complying with the certification and
packaging requirements in Section 2.3.1, LifeNet will insert the Product into
the Final Packaging. LifeNet will notify Osteotech in writing within five (5)
Business Days after LifeNet becomes aware of any visible defects in the Initial
Packaging for the Product. In the event of any such notification, the Product
will then be promptly returned to Osteotech to be remedied as appropriate in
accordance with the terms of this Agreement.

            2.3.4 Distribution and Invoicing of Product by LifeNet. LifeNet will
distribute or cause to be distributed Product to Customers and use Reasonable
Efforts to contemporaneously invoice Customers therefor. LifeNet will be
responsible for maintaining for a period of at least 10 years after the date of
distribution of Product tracking records identifying the Customer to whom
Product was distributed by LifeNet or its designees.

      2.4 License of LifeNet Technology to Osteotech. LifeNet hereby confirms
that LifeNet has granted to Osteotech, pursuant to the terms and conditions of
the Primary Agreement, a limited, non-exclusive, royalty-free license for
Osteotech to use LifeNet Technology for purposes of making Product from tissue
supplied by LifeNet.

      2.5 License of Osteotech Patents to LifeNet. Osteotech hereby confirms
that Osteotech has granted to LifeNet, pursuant to the terms and conditions of
the Primary Agreement, a limited, non-exclusive, royalty-free license for
LifeNet to use the technology covered by claims in the Osteotech Patents for
purposes of processing and distributing Product.

      2.6 Covenant Not to Sue. Each of Osteotech and LifeNet hereby waives any
and all rights or claims against DePuy (or its Affiliates), including the right
to sue, for any claims that the actions of DePuy (or its promotional agents)
performed in accordance with the terms of this Agreement constitute an alleged
infringement of the intellectual property of Osteotech or

                                      E-28
<PAGE>

LifeNet related to the Products, as the case may be, including claims based on
theories of patent, trademark, trade name, or copyright infringement.

      2.7 Determination of Tissue Providers. LifeNet will have the sole right to
determine the tissue bank providers of all bone tissue to be used in the
Products, provided the identity of such tissue bank provider is first disclosed
to Osteotech and DePuy and each of Osteotech and DePuy is given a reasonable
opportunity to lodge a non-binding objection to the use of tissue provided by
such tissue bank provider. Notwithstanding the fact that tissue may be provided
by such other tissue banks, LifeNet shall be responsible as to Osteotech and
DePuy in all respects with LifeNet's obligations under this Agreement and the
Primary Agreement with regard to such tissue as if such tissue were provided
directly by LifeNet.

      2.8 In the Event of an Insufficient Supply of Tissue. In the event that
LifeNet is unable to supply enough tissue directly to meet the demand for
Products, then LifeNet shall use Reasonable Efforts to secure additional tissue
providers as contemplated in Section 2.7 hereof. If LifeNet is unable to secure
additional tissue providers as contemplated in Section 2.7 hereof and LifeNet
has complied with the Tissue Priority Guidelines, then LifeNet will not have
liability to Osteotech or DePuy for LifeNet's failure to supply, whether
directly or indirectly, enough tissue to meet the demand for Products.

      2.9 Determination of Product Types and Amounts. LifeNet *** shall have the
sole right to determine the number and location of distribution centers for
Product. LifeNet represents and agrees that each of such distribution centers
is, or will be prior to the distribution of any Product through or from such
center, as required by applicable Laws and Rules, registered with the FDA and
all applicable state and local authorities. If requested by LifeNet, DePuy may,
but shall not be required to, assume any of the responsibilities of LifeNet set
forth in this Section 2.9.

      2.10 ***

SECTION 3 EXCLUSIVITY OF PROMOTION

      3.1 Generally. Pursuant to Section 4.9 of the Primary Agreement, Osteotech
appoints DePuy as the exclusive promotional agent for the Products in the
Territory for the Field; provided, however, that such appointment shall in no
way restrict LifeNet from acting as its own promotional agent for the Products
in the Territory for the Field, so long as DePuy receives the compensation to
which it is entitled for any distribution of Products in the Territory for the
Field that are the result of LifeNet's promotional efforts on its own behalf.
LifeNet agrees not to appoint another promotional agent for the Products so long
as DePuy is the exclusive promotional agent in accordance with the terms of this
Agreement.

      3.2 Promotional Restrictions on DePuy. Until ***, DePuy Orthopaedics
agrees that it will not promote, offer, provide, sponsor, recommend, sanction,

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-29
<PAGE>

approve, endorse, distribute and/or sell in the Territory for the Field, whether
directly or indirectly, any DBM Carrier Product other than the Products.
Notwithstanding the foregoing, certain of DePuy Orthopaedics' independent
distributors shall be able to continue to promote and distribute DBM Carrier
Products in the Territory for the Field other than the Products, pursuant to
Pre-Existing Distribution Agreements. DePuy represents and warrants to LifeNet
and Osteotech that the Pre-Existing Distribution Agreements are applicable and
will be applicable during the term of this Agreement to less than *** of DePuy
Orthopaedics' sales force (taking into account both employees of DePuy
Orthopaedics and employees of independent distributors retained by DePuy
Orthopaedics) and; further, provided that DePuy Orthopaedics will use all
Reasonable Efforts (which, at a minimum, include the termination of each
Pre-Existing Distribution Agreement at the earliest possible date under the
terms of the Pre-Existing Distribution Agreement without liability to DePuy
Orthopaedics) to cause all such independent distributors which may be promoting
or distributing DBM Carrier Products other than Products in the Territory for
the Field to cease the promotion and distribution of such DBM Carrier Products
as soon as practicable after the Effective Date without causing such independent
distributors to breach any contract that may be in place as of the Effective
Date. DePuy Orthopaedics may promote, offer, provide, sponsor, recommend,
sanction, approve, endorse, distribute and/or sell *** any DBM Carrier Product
in the Territory for the Field other than Products; provided that at least ***
prior to any distribution of such DBM Carrier Product in the Territory for the
Field, DePuy Orthopaedics shall have provided Osteotech and LifeNet with a DBM
Notice of Sale. Notwithstanding the foregoing, DePuy Orthopaedics shall not be
restricted hereby from developing and DePuy AcroMed shall not be restricted
hereby from promoting, offering, providing, sponsoring, recommending,
sanctioning, approving, endorsing, distributing and/or selling any products
(including DBM Carrier Products) that are not Products. Nothing contained in
this Section 3.2 shall have any effect on the rights and obligations of the
Parties under Sections 10.12 and 10.14 hereof.

      3.3 Limited Restrictions on LifeNet. LifeNet shall not be restricted, in
any way, from providing allograft tissue for or participating in the processing,
promotion and/or distribution of Carrier Allografts other than Products. Nothing
herein shall relieve LifeNet of complying with its obligations under this
Agreement or the Primary Agreement or be interpreted to grant to LifeNet any
license to utilize any valid, non-expired patent owned by Osteotech except as
specifically provided in this Agreement.

      3.4 Grafton(R) Exclusion. Notwithstanding the fact that the Products may
have some of the same general characteristics as Osteotech's Grafton(R) DBM
products, the Parties agree that Grafton(R) DBM products remain a product that
Osteotech may continue to market and promote in any manner, either on its own
and/or with or through any third party that it determines in its sole
discretion. Nothing contained herein shall restrict Osteotech from processing,
marketing, promoting and/or distributing Carrier Allografts other than the
Products, provided such Carrier Allografts other than the Products do not
contain either of the Required Characteristics set forth in EXHIBIT A hereto.

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-30
<PAGE>

SECTION 4 RELATIONSHIP OF PARTIES; BUDGET

      4.1 Relationship of the Parties. The relationship between the Parties set
forth in this Agreement will not constitute and will not be construed as
constituting a partnership or a relationship of agent and principal. No Party
shall, under any circumstances act as or represent itself to be a partner, agent
or a representative of any other Party. No Party shall have any responsibility
for the firing, compensation, or employee benefits of any other Party's
employees. No employee or representative of any Party shall have any authority
to bind or obligate any other Party for any sum or in any manner whatsoever, or
to create or impose a contractual or other liability on any other Party without
such other Party's authorized written approval. For all purposes, and
notwithstanding any other provision of this Agreement to the contrary, the legal
relationship of the Parties under this Agreement shall be that of independent
contractors.

      4.2 Promotional Budget. For each Contract Year DePuy and LifeNet shall
prepare and deliver to Osteotech a Promotional Budget that will include the
costs of Promotional Materials prepared and designed by LifeNet as well as all
additional promotional activities. The Promotional Budget for the first Contract
Year will be developed within sixty (60) calendar days after the Effective Date
and will be attached hereto as EXHIBIT E. The Promotional Budget for subsequent
Contract Years will be developed by DePuy and LifeNet and be distributed by
DePuy to Osteotech not less than sixty (60) calendar days prior to the end of
the then preceding Contract Year and, when so distributed, shall be attached
hereto as a revised EXHIBIT E. DePuy shall bear all costs and expenses
associated with the Promotional Budget other than the costs connected with the
preparation of the Promotional Materials or such other specific costs assumed at
LifeNet's sole discretion, by LifeNet.

SECTION 5 OBLIGATIONS AND REPRESENTATIONS OF THE PARTIES

      5.1 Regulatory Matters.

            5.1.1 Product Complaints. DePuy will forward Product Complaints to
LifeNet within five (5) Business Days after DePuy's receipt of such Product
Complaints and LifeNet, in turn, will forward such Product Complaints to
Osteotech within five (5) Business Days after LifeNet's receipt of such Product
Complaints to the extent such Product Complaint relates or may relate to the
processing of the Product. LifeNet will log, investigate and close all Product
Complaints and timely file, as a result of a Product Complaint, all required
reports or other notices with appropriate regulatory authorities. DePuy and
Osteotech will use Reasonable Efforts to assist LifeNet in conducting any
investigation of a Product Complaint if and as requested by LifeNet.

            5.1.2 Adverse Reaction Reports. In the case where a Party learns of
any Adverse Reaction Report or of any other information pertaining to potential
safety concerns of a Product, such Party shall notify the other Parties of such
Adverse Reaction Report or information as promptly as is practicable (but in no
event more than five (5) Business Days after receiving such report or
information) by telephone or telefax and shall provide the notified Parties with
relevant supporting documentation pertaining to the potential safety concerns of
a Product. The Parties will meet promptly thereafter to determine the most
appropriate way to handle any such Adverse Reaction Report or information. If
reporting information relating to any Adverse

                                      E-31
<PAGE>

Action Report or potential safety concerns related to a Product to any authority
or administrative agency is necessary, LifeNet will be responsible for such
reporting.

            5.1.3 Recall or Corrective Action.

                  (a) Generally. If one of the Parties believes that a recall or
corrective action, including, without limitation, a suspension of Product
distribution or promotion or Customer or recipient notification, should be
instituted for any reason with respect to one or more Products, such Party shall
promptly contact the other Parties. The Parties shall exchange all relevant
information and data to assess the need for a recall or corrective action and
shall in good faith attempt to reach agreement as to what actions, if any,
should be initiated. If a recall or corrective action is implemented by LifeNet,
in its sole discretion, then all of the Parties shall cooperate fully with one
another and shall comply with applicable FDA requirements, if any, in assisting
LifeNet with the implementation of the action as necessary, including, but not
limited to, providing the names of recipients of the subject Products and
assisting in the preparation of any reports that must be submitted to the FDA
and any other regulatory agency. LifeNet agrees that it will not unreasonably
refuse to implement a recall or corrective action.

                  (b) DePuy Right to Initiate a Recall or Corrective Action. In
the event that DePuy is the only Party that believes that a recall or corrective
action should be instituted, after the Parties have consulted one another
pursuant to Section 5.1.3(a), then DePuy may direct LifeNet to implement such
recall or corrective action. In the event of such a recall or corrective action,
all of the Parties shall cooperate fully with one another and shall comply with
applicable FDA requirements, if any, in assisting LifeNet with the
implementation of the actions as necessary.

            5.1.4 Reimbursement for Recalls.

                  (a) Generally. In the event that a recall or corrective action
is initiated as a result of a Product's failure to meet its specifications, a
violation of Laws and Rules, a deviation from the standards established by the
AATB, or a health risk to a recipient, Osteotech to the extent it is responsible
for the failure, violation deviation or health risk or LifeNet to the extent it
is responsible for the failure, violation, deviation or health risk, shall
reimburse each of the other Parties for all out-of-pocket expenses they
reasonably incur as a result of the recall or corrective action.

                  (b) Recalls or Corrective Actions Initiated by DePuy. In the
event that a recall or corrective action is initiated by DePuy pursuant to
Section 5.1.3(b), the Parties will be responsible for reimbursing the other
Parties as follows:

                  (i)   In the event that the Parties determine that the recall
                        or corrective action was necessary, as indicated by the
                        evaluation of the Products affected by the recall or
                        corrective action, then either LifeNet or Osteotech, as
                        the case may be, will reimburse each of the other
                        Parties in accordance with Section 5.1.4(a) above.

                                      E-32
<PAGE>

                  (ii)  In the event that the Parties determine that the recall
                        or corrective action was not necessary, as indicated by
                        the evaluation of the Products affected by the recall or
                        corrective action, then DePuy will reimburse each of
                        Osteotech and LifeNet, as the case may be, for (A) one
                        hundred percent (100%) of the costs incurred for the
                        return of the Products; (B) all out of pocket expenses
                        incurred in the evaluation of the recalled Products; (C)
                        all service fees previously paid to either Osteotech or
                        DePuy by LifeNet for Products actually recalled sold
                        prior to the recall or corrective action; and (D) the
                        cost of goods sold for any Products that are recalled,
                        but not resalable, proximately caused by the recall or
                        corrective action, minus the amount of any service fees
                        collected prior to such recall or corrective action.

                  (c) Disputes. Any disputes regarding any Party's reimbursement
obligations pursuant to this Section 5.1.4, including disputes regarding whether
a recall or corrective action initiated by DePuy pursuant to Section 5.1.3(b)
hereof was necessary, shall be resolved in accordance with the terms of Section
12 hereof.

            5.1.5 Notice of Regulatory Action. Each Party shall provide the
other Party with prompt written notice and copies of any inquiries from or
positions taken by the FDA (e.g. 483 notices of observations, warning letters,
untitled letters or actions, threats of actions, inspections and/or results of
inspections) or any other government agency or standard setting body which may
significantly affect the manufacturing, processing, promotion or distribution of
any Product, including, without limitation, whether any Product (or related
product) requires FDA clearance or approval.

            5.1.6 510(k) Premarket Notification. In the event the FDA determines
that a Product produced under this Agreement requires the submission of a 510(k)
Premarket Notification and the Product contains only glycerol and bone
(including residual trace elements relating to the processing of such Product),
then Osteotech will be responsible for submitting such 510(k) Premarket
Notification at its own cost. In the event of the submission by Osteotech of
such a 510(k) Premarket Notification, Osteotech shall own such 510(k) Premarket
Notification. Osteotech agrees that it will provide to LifeNet any information
used in connection with the 510(k) Premarket Notification submission upon
request from LifeNet and allow LifeNet to rely on, and have access to, such
information, and such information shall be treated as Confidential Information.
In the event such 510(k) Premarket Notification is submitted, Osteotech
authorizes LifeNet to distribute, and DePuy to promote, Product pursuant to any
approvals granted per such 510(k) Premarket Notification.

      5.2 LifeNet Obligations.

            5.2.1 Design of the Promotional Materials. LifeNet shall at its cost
design and prepare the Promotional Materials and shall provide DePuy and
Osteotech an opportunity to review and comment on the prepared Promotional
Materials as set forth in

                                      E-33
<PAGE>

Sections 5.3.1 and 5.4.2. LifeNet shall not be required to create or develop any
new information or data which it does not possess at the time of preparation of
the Promotional Materials. LifeNet's use of all information and data provided by
Osteotech pursuant to Section 5.4.2 will comply with the restrictions and use
limitations specified therein.

            5.2.2 Invoicing. LifeNet will use Reasonable Efforts to deliver or
cause to be delivered all invoices for Products distributed to Customers in the
Territory by LifeNet (or on LifeNet's behalf by its designees, as LifeNet may
determine in its sole discretion) contemporaneously with the distribution of the
Product. It is expressly understood that full power and authority for all
collections rests with LifeNet, which shall exercise complete control over the
approval of all Customer credits, orders, and contracts.

            5.2.3 Distribution of Product to Customers. LifeNet (with the
support of its designees) will be solely responsible for distribution of
Products to Customers. LifeNet shall (with the support of its designees) manage
and fill all orders for the Products and may facilitate delivery of such
Products. LifeNet shall ship and deliver all Products ordered pursuant to this
Agreement either directly from LifeNet by the Customer or indirectly by the
Customer from an agent authorized by DePuy either directly to the Customer or
through such designees for facilitated delivery to Customers. As among LifeNet,
Osteotech and DePuy, all costs of transportation and shipping shall be paid by
LifeNet and LifeNet may bill Customers for such costs. In no event will
Osteotech or DePuy be responsible for transportation and shipping costs. If a
Product is distributed to a DePuy authorized agent and such agent loses such
Product or the Product becomes unusable while in the possession of such agent,
DePuy shall reimburse LifeNet in an amount equal to *** of the End User Fee for
such Product.

            5.2.4 Return of Product. DePuy shall refer to LifeNet all requests
or inquiries related to the return of Product as specified in Section 5.3.4
hereof.

      5.3 DePuy Obligations.

            5.3.1 Approval of Promotional Materials. DePuy shall provide written
comments on the Promotional Materials to LifeNet within ten (10) Business Days
("DEPUY COMMENT PERIOD") after submission by LifeNet, and failure to provide
such written comments within the DePuy Comment Period shall be deemed to be
approval of such Promotional Materials by DePuy. DePuy's use of all information
and data provided by Osteotech pursuant to Section 5.4.2 will comply with the
restrictions and use limitations specified therein.

            5.3.2 Sales Force Training. DePuy shall, consistent with its normal
business practices and legal requirements and in the manner determined
reasonable in the sole discretion of DePuy, train at regional and national sales
meetings its designated sales force to promote each Product in the Territory for
the Field.

            5.3.3 Commission Payments. ***

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-34
<PAGE>

            5.3.4 No Order Fulfillment by DePuy; Returns. DePuy shall promptly
refer any order for any Product to LifeNet so that such order can be processed
by LifeNet on a timely basis. DePuy shall not accept returns of Product from the
field and shall refer such returns or requests or inquiries relating to returns
of Product to LifeNet's customer service representatives for handling in
accordance with LifeNet's policy.

            5.3.5 Sales Forecast. Within ten (10) Business Days after the
Effective Date, DePuy shall provide Osteotech and LifeNet with the Initial
Forecast. Subsequent to providing the Initial Forecast, DePuy shall provide to
Osteotech and LifeNet within ten (10) Business Days after the first calendar day
of each month a rolling non-binding twelve (12) calendar month forecast of sales
for each Product by product code.

      5.4 Osteotech Obligations.

            5.4.1 Development and Processing of the Products. Osteotech will
develop and process each of the Products in accordance with this Agreement and
the Primary Agreement.

            5.4.2 Contribution to the Promotional Materials. Osteotech shall
provide LifeNet with such information and data as Osteotech shall have
concerning each of the Products as LifeNet shall reasonably request in order to
assist LifeNet in designing Promotional Materials and shall provide such
information within ten (10) Business Days after such request by LifeNet. In
addition, Osteotech shall provide LifeNet with existing clinical data taken from
published and unpublished Grafton(R) studies (whether now existing or existing
in the future) which demonstrate that glycerol is a safe and effective carrier
for bone tissue. Osteotech shall provide written comments to correct any
inaccuracies present in the technical information set forth in the Promotional
Materials to LifeNet within thirty (30) calendar days ("OSTEOTECH COMMENT
PERIOD") after submission of such Promotional Materials to Osteotech by LifeNet,
and failure to provide such written comments within the Osteotech Comment Period
shall be deemed to be approval of such Promotional Materials by Osteotech.
Osteotech shall not be required to create or develop any new information or data
which it does not possess at the time of the request for information from
LifeNet, but shall promptly furnish any new information or data related to the
Products as such new information or data is created or acquired in the normal
course of its business. If information or data concerning the Products is
reasonably requested by DePuy, Osteotech agrees to provide DePuy with the
necessary information, subject to the terms of this Section 5.4.2. Each of
LifeNet and DePuy, as the case may be, may use the clinical data provided by
Osteotech in accordance with this Section 5.4.2 in the Promotional Materials
that LifeNet designs and prepares hereunder or otherwise only to demonstrate
that glycerol is a safe and effective carrier for bone tissue. Neither LifeNet
nor DePuy shall use such clinical data or any clinical data concerning
Grafton(R) to demonstrate that a Product is osteoinductive or that a Product's
osteoinductive capacity is substantially similar to the osteoinductive capacity
of Grafton(R). LifeNet and DePuy shall have the permission of Osteotech to
reproduce and adapt all information and data supplied by Osteotech pursuant to
this Section 5.4.2.

            5.4.3 No Order Taking by Osteotech; Returns. Osteotech shall not
take any order for any Product, and shall promptly refer any order for any
Product to LifeNet so that such order can be processed by LifeNet on a timely
basis. Osteotech shall not accept returns of

                                      E-35
<PAGE>

Product from the field and shall refer such returns or requests or inquiries
relating to returns of Product to LifeNet's customer service representatives for
handling in accordance with LifeNet's policy.

      5.5 Representations, Warranties, and Covenants of the Parties.

            5.5.1 All Parties. Each Party represents and warrants to each of the
other Parties that: (a) it has full power and authority to execute and deliver
this Agreement and to perform its obligations hereunder, and such execution,
delivery and performance hereunder does not and will not violate or breach and
will not conflict with or constitute a default under any agreement, contract,
commitment or obligation to which such Party, or to the best of its knowledge,
any of its Affiliates is a party or by which it is bound; and (b) it has not
granted and will not grant during the term of this Agreement or any renewal
thereof, any conflicting rights, licenses, consents or privileges with respect
to the rights granted herein.

            5.5.2 Osteotech.

                  (a) Laws and Rules. Osteotech represents and warrants that it
shall comply, to the extent applicable to Osteotech's activities under this
Agreement, with all Laws and Rules relating to the recovery of donor tissue and
the processing, packaging, labeling, supply and distribution of the Products and
its internal procedures which implement such Laws and Rules.

                  (b) Ownership of Intellectual Property. Osteotech represents
and warrants that, to the best of its knowledge, (i) Osteotech owns all
necessary rights, title and interest in and to, or otherwise has the necessary
licenses to, the Osteotech Patents to authorize LifeNet and DePuy to carry out
their respective obligations under this Agreement, (ii) no academic institution,
member of an academic institution, corporation or other entity, or any local,
state or federal government holds any unlicensed or unassigned property rights
in any Osteotech Patent and (iii) the processing, use and promotion of the
Products in accordance with the terms of this Agreement do not infringe any
third party's rights under any patent, copyright, trademark or trade secret
right (provided that Osteotech makes no representation or warranty that rights
in LifeNet Technology or intellectual property licensed under Section 2.4 of
this Agreement are not used in such processing, use and promotion). Except as
expressly stated herein, Osteotech makes no other warranties, express or
implied, as to the Osteotech Patents or third party patents.

                  (c) Sufficiency of License of Osteotech Patents. Osteotech
hereby represents and warrants that the license to use Osteotech Patents granted
to LifeNet in the Primary Agreement is sufficient to cover all Products covered
by this Agreement and all activities of LifeNet in processing and distributing
such Products as contemplated by this Agreement.

                  (d) Specifications. Osteotech represents and warrants that the
Products, upon completion of processing of such Products by Osteotech, shall
meet the specifications set forth in EXHIBIT A hereto and be free from defects
in processing, including materials involved in the processing of the Product,
but excluding Allograft Bone Tissue provided by LifeNet, that adversely affect
Product safety.

                                      E-36
<PAGE>

                  (e) No Advertising or Promotional Activities. Osteotech
represents and warrants that it will not conduct any advertising or promotional
activities with respect to the Products other than providing information and
reviewing the Promotional Materials pursuant to Section 5.4.2 hereof.

            5.5.3 LifeNet.

                  (a) Laws and Rules for Supply of Tissue. LifeNet represents
and warrants that all Allograft Bone Tissue supplied by LifeNet in connection
with this Agreement shall be provided in accordance with applicable Laws and
Rules and its internal procedures which implement such Laws and Rules. LifeNet
further represents that all donor tissue that it receives from tissue providers
and delivers as Allograft Bone Tissue to Osteotech for processing under this
Agreement will comply with applicable Laws and Rules and its internal procedures
which implement such Laws and Rules.

                  (b) Laws and Rules for Recovery of Tissue. LifeNet represents
and warrants that it shall comply, to the extent applicable to LifeNet's
activities under this Agreement, with all applicable Laws and Rules (including
without limitation NOTA) relating to the recovery of donor tissue and the
processing, packaging, labeling, supply and distribution of the Products and
with LifeNet's internal procedures which implement such Laws and Rules.

                  (c) AATB Accreditation. LifeNet represents and warrants that
it is and will be an AATB accredited tissue bank and registered with the FDA.

                  (d) Ownership of Intellectual Property. LifeNet represents and
warrants that, to the best of its knowledge, the use of the LifeNet Technology
to process the Products in accordance with the terms of this Agreement and the
Primary Agreement does not infringe any third party's rights under any patent,
copyright, trademark or trade secret right (provided that LifeNet makes no
representation or warranty concerning the use of any Osteotech Patents in
connection with any such processing, use or promotion). LifeNet further
represents and warrants that the LifeNet Patents listed in EXHIBIT G are all the
patents owned or controlled by LifeNet that are reasonably necessary for the
activities of Osteotech and DePuy with respect to Products *** as contemplated
by this Agreement.

                  (e) Sufficiency of License of LifeNet Technology. LifeNet
represents and warrants that the license to use LifeNet Technology granted to
Osteotech by LifeNet pursuant to the terms and conditions of the Primary
Agreement is sufficient to cover all Products covered by this Agreement and all
activities of Osteotech in making such Products as contemplated by this
Agreement.

                  (f) Specifications. LifeNet represents and warrants that the
Allograft Bone Tissue, upon completion of processing of such Allograft Bone
Tissue by LifeNet,

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-37
<PAGE>

shall be free from defects in processing, including materials involved in the
processing of the Allograft Bone Tissue, that adversely affect Product safety.

            5.6 DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NO
PARTY GUARANTEES OR MAKES ANY REPRESENTATION OR WARRANTY WHATSOEVER, WHETHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE.

SECTION 6 COMPENSATION

            6.1 End User Fees

                  6.1.1 ***

                  6.1.2 ***

                  6.1.3 Discounts to End User Fees. LifeNet will not commit to
any discount of End User Fees for Product without the consent of DePuy and DePuy
shall have no authority and will not commit to any discount of End User Fees for
Product without the consent of LifeNet.

            6.2 Payment of Service Fees.

                  6.2.1 Osteotech Service Fee. ***

                  6.2.2 ***

                  6.2.3 ***

                  6.2.4 ***

                  6.2.5 ***

                  6.2.6 ***

                  6.2.7 ***

      6.3 Compensation and Expenses.

                  6.3.1 DePuy Service Fee is Sole Compensation to DePuy. The
DePuy Service Fees to be paid to DePuy by Osteotech (or by LifeNet on behalf of
Osteotech pursuant to Section 6.2.2 hereof) pursuant to this Agreement shall be
the sole and exclusive compensation to DePuy for any and all services performed
pursuant to this Agreement and costs associated

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-38
<PAGE>

therewith; provided, that nothing herein shall (i) prevent DePuy from receiving
any expressly reimbursable costs and expenses and/or (ii) limit LifeNet's and/or
Osteotech's obligations to DePuy arising in connection with this Agreement.
DePuy shall bear the entire cost and expense of conducting its business.

                  6.3.2 Osteotech Service Fee is Sole Compensation to Osteotech.
The Osteotech Service Fees to be paid to Osteotech by LifeNet pursuant to this
Agreement shall be the sole and exclusive compensation to Osteotech for any and
all services performed pursuant to this Agreement and costs associated
therewith; provided, that nothing herein shall (i) prevent Osteotech from
receiving any expressly reimbursable costs and expenses and/or (ii) limit
LifeNet's and/or DePuy's obligations to Osteotech arising in connection with
this Agreement. Osteotech shall bear the entire cost and expense of conducting
its business. Notwithstanding the provisions of this Section 6.3.2, Osteotech
will be entitled under certain conditions to receive reimbursement for its
remaining Inventory Supply pursuant to Section 6.4.

                  6.3.3 LifeNet Fee is Sole Compensation to LifeNet. The LifeNet
Fee to be retained by LifeNet pursuant to this Agreement shall be the sole and
exclusive compensation to LifeNet for any and all services performed pursuant to
this Agreement and costs associated therewith; provided, that nothing herein
shall (i) prevent LifeNet from receiving any expressly reimbursable costs and
expenses and/or (ii) limit Osteotech's and/or DePuy's obligations to LifeNet
arising in connection with this Agreement. LifeNet shall bear the entire cost
and expense of conducting its business. Notwithstanding the provisions of this
Section 6.3.3, LifeNet will be entitled under certain conditions to receive
reimbursement for its remaining Inventory Supply pursuant to Section 6.4.

            6.4 Inventory Supply and Reimbursements.

                  6.4.1 Inventory. Without limiting the other provisions of
Section 6 hereof, in order to avoid backorders and to provide a sufficient
supply of Products for timely distribution by LifeNet, Osteotech will, at its
own cost, process and create the initial finished goods inventory of Products
under this Agreement by processing an initial finished goods inventory of
Products sufficient to meet ***. Subject to the Tissue Priority Guidelines in
Section 1.73, for the duration of this Agreement Osteotech and LifeNet together
will continue to process and maintain the Targeted Inventory Level.
Notwithstanding Osteotech's obligation to maintain the Targeted Inventory Level,
in the event that LifeNet does not supply Osteotech with sufficient Allograft
Bone Tissue to meet or sustain the Targeted Inventory Level, Osteotech will not
be considered to have breached the terms of this Section 6.4.1. In addition,
because nothing in this Section 6.4.1 affects *** in the event of a dispute
between any of the Parties related to the Targeted Inventory Level, Osteotech
will not be considered to have breached the terms of this Section 6.4.1, if the
amount of finished goods inventory available varies from the Targeted Inventory
Level due to ***.

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-39
<PAGE>

                  6.4.2 Carry-Over Period Conditions. In the event this
Agreement is terminated in a manner described in Section 6.4 hereof, the
following conditions (in addition to the other surviving provisions of this
Agreement) will become immediately applicable, and in the event this Agreement
is terminated as to a particular Product, the following conditions with respect
to such Product shall become immediately applicable.

                        (a) Generally. Upon such termination (A) no Product
shall be distributed if the date of such distribution would be reasonably likely
to cause such Product to be implanted in a patient after the expiration of its
shelf life; (B) LifeNet shall deliver no additional Allograft Bone Tissue to
Osteotech pursuant to this Agreement and Osteotech shall not create any
additional work-in-process inventory during the Carry-Over Period; and (C)
notwithstanding such termination of this Agreement, all promotional, processing
and distribution activities relating to the Inventory Supply during the
Carry-Over Period shall be conducted in accordance with the terms of this
Agreement and the provisions of this Agreement shall apply to all such
activities. Nothing contained under this 6.4.2(a) will affect the obligations of
LifeNet or Osteotech under the Primary Agreement.

                        (b) Adjustments to Reimbursements. In the event that
there is any reimbursement due by DePuy to Osteotech under Sections 6.4.3 or
6.4.13 for Inventory Carrying Costs for Product for which Osteotech has been
paid its Osteotech Service Fee, at the request of LifeNet, DePuy shall pay
Osteotech's Inventory Carrying Costs for such Product to LifeNet and Osteotech
shall reimburse LifeNet an amount equal to the difference between (i) such
Osteotech Service Fee, minus any DePuy Service Fee that was not received by
Osteotech, and (ii) Osteotech's Inventory Carrying Cost of such Products. In any
instance where Osteotech is to reimburse LifeNet for Inventory Carrying Costs
for inventory for which LifeNet has paid the Osteotech Service Fee, then
LifeNet's Inventory Carrying Costs for inventory shall include the amount of
such Osteotech Service Fee, minus any DePuy Service Fee that was not received by
Osteotech.

                        (c) LifeNet to Act as Temporary Promotional Agent. If
DePuy's engagement as the promotional agent under this Agreement shall terminate
or terminate as to Product(s), as the case may be, in a manner described in
Section 6.4.3(b) hereof, then LifeNet will automatically become a temporary
promotional agent under this Agreement, or as to such Product(s), as the case
may be, as of the effective date of such notice of termination. In its role as a
temporary promotional agent, LifeNet shall assume the same responsibilities as
DePuy under the terms of this Agreement for the promotion of the Products and
LifeNet shall be entitled to retain the DePuy Service Fee under this Agreement,
or as to such Product(s), as the case may be. LifeNet's term as a temporary
promotional agent will terminate upon the earlier of (i) an appointment of a
substitute promotional agent in accordance with the terms of Section 6.4.2(d)
hereof, or (ii) the end of the applicable Carry-Over Period.

                        (d) Appointment of Substitute Promotional Agent. Upon
the termination of DePuy's engagement as the promotional agent under this
Agreement or the termination of DePuy's engagement as the promotional agent as
to Product(s), as the case may be, and for the duration of any applicable
Carry-Over Period, Osteotech and LifeNet shall have the right to negotiate with,
and appoint, a mutually acceptable promotional agent to perform the remaining
obligations of DePuy under this Agreement. In the event that such a promotional

                                      E-40
<PAGE>

agent is appointed, LifeNet and Osteotech shall provide DePuy with thirty (30)
calendar days' written notice thereof. At the end of such thirty (30) calendar
day period, DePuy shall be relieved of its remaining promotional and
reimbursement obligations under Sections 6.4.3 and 6.4.13 hereof, under this
Agreement in its entirety or as to Product(s), as the case may be, and DePuy
will no longer be entitled to receive the DePuy Service Fee for any Product
distributed under this Agreement and no longer promoted by DePuy.

                  6.4.3 Carry-Over Period and Reimbursement by DePuy.

                        (a) In the event this Agreement is (i) terminated by
DePuy pursuant to Sections 10.3 (Bankruptcy) or 10.9 (Change in Control of
Osteotech) hereof, or (ii) terminated as to Product(s) pursuant to Section 10.6
(Invalidity of Osteotech Patents) hereof, or (iii) terminated by Osteotech
pursuant to Section 10.14 (Corrective Payments by DePuy) hereof, or (iv) in the
event this Agreement is not renewed pursuant to Section 10.1 (Term) hereof based
upon a notice of termination sent thereunder by DePuy, then, in each such case,
DePuy shall have the right during the Carry-Over Period to continue to promote
the Products in order to allow for the distribution of the Inventory Supply. If
DePuy shall fail to actively promote the Products comprising the Inventory
Supply during the Carry-Over Period or if there shall be any Inventory Supply
remaining undistributed at the end of the Carry-Over Period, each of Osteotech
and LifeNet shall deliver a statement signed by its chief financial officer
certifying (A) as to the Inventory Carrying Costs for the Inventory Supply then
on hand and (B) that such Inventory Carrying Costs have been recorded by
Osteotech and LifeNet, respectively, in accordance with generally accepted
accounting principles and in a manner which is consistent with Osteotech's or
LifeNet's past practice, respectively. DePuy shall pay, subject to the terms of
Section 6.4.2, such Inventory Carrying Costs to Osteotech and LifeNet, as the
case may be, within thirty (30) calendar days after its receipt of both such
certifications by Osteotech's and LifeNet's chief financial officer,
respectively.

                        (b) If this Agreement is (i) terminated by either
Osteotech or LifeNet pursuant to Section 10.4 (Material Breach of
Representations) hereof due to DePuy's material breach of its representations,
warranties or covenants contained in this Agreement, or (ii) terminated as to
Product(s) by either Osteotech or LifeNet pursuant to Section 10.7 (Recall or
Corrective Action) and the recall or corrective action that forms the basis for
the right to terminate this Agreement as to such Product(s) is the result of an
action or omission of DePuy, then, in each such case, DePuy shall not have the
right to continue to promote the Products during the Carry-Over Period. If there
shall be any Inventory Supply remaining undistributed on the effective date of
the termination in accordance with this Section 6.4.3(b), then each of Osteotech
and LifeNet shall deliver a statement signed by its chief financial officer
certifying (A) as to the Inventory Carrying Costs for the Inventory Supply then
on hand and (B) that such Inventory Carrying Costs have been recorded by
Osteotech and LifeNet, respectively, in accordance with generally accepted
accounting principles and in a manner which is consistent with Osteotech's or
LifeNet's past practice, respectively. DePuy shall pay the Inventory Carrying
Costs to Osteotech and LifeNet, respectively, within thirty (30) calendar days
of its receipt of both such certifications by Osteotech's and LifeNet's chief
financial officer, respectively.

                                      E-41
<PAGE>

                        (c) DePuy shall have no obligation to pay to Osteotech
or LifeNet, respectively, Osteotech's or LifeNet's Inventory Carrying Costs for
any remaining Inventory Supply, except as provided in this Section 6.4.3 and
Section 6.4.13 hereof.

            6.4.4 Termination by Osteotech or LifeNet under Sections 10.1 (Term)
or 10.3 (Bankruptcy). In the event this Agreement is terminated by Osteotech or
LifeNet (the terminating Party defined as the "Terminating Party" and the other
Party defined as the "Non-Terminating Party" for purposes of this Section 6.4.4)
under Sections 10.1 or 10.3 hereof, and there shall be any Inventory Supply
remaining undistributed at the time that the termination becomes effective, then
the Non-Terminating Party shall deliver a statement to the Terminating Party
signed by its chief financial officer certifying (A) as to the Inventory
Carrying Costs for the Inventory Supply then on hand and (B) that such Inventory
Carrying Costs have been recorded by the Non-Terminating Party in accordance
with generally accepted accounting principles and in a manner which is
consistent with the Non-Terminating Party's past practice. The Terminating Party
shall pay such Inventory Carrying Costs to the Non-Terminating Party, within
thirty (30) calendar days after its receipt of such certification by the
Non-Terminating Party's chief financial officer. If LifeNet is the
Non-Terminating Party, then LifeNet shall be permitted to distribute the
Inventory Supply and if Osteotech has paid LifeNet LifeNet's Inventory Carrying
Costs in accordance with this Section 6.4.4, then LifeNet will pay to Osteotech
the Osteotech Service Fee in accordance with the terms of Section 6.2.1. If
Osteotech is the Non-Terminating Party and LifeNet has paid Osteotech its
Inventory Carrying Costs in accordance with this Section 6.4.4, then LifeNet
shall be permitted to distribute the Inventory Supply and retain all fees
collected therefor (i.e., without payment of the Osteotech Service Fee or the
DePuy Service Fee).

            6.4.5 Termination by Osteotech or LifeNet under Section 10.2
(Termination of Primary Agreement). In the event this Agreement is terminated,
or terminated as to Product(s), as the case may be, pursuant to Section 10.2
hereof, then LifeNet or Osteotech, as the case may be, will be obligated for
reimbursing the other for any remaining Inventory Supply as follows:

                  (a) In the event the Primary Agreement is terminated by
Osteotech or LifeNet, (the terminating Party defined as the "Terminating Party"
and the other Party defined as the "Non-Terminating Party" for purposes of this
Section 6.4.5(a)) under Sections 11.1 (Initial and Renewal Terms) or 11.2
(Bankruptcy) of the Primary Agreement, and there shall be any Inventory Supply
remaining undistributed at the time that the termination becomes effective, then
the Non-Terminating Party shall deliver a statement to the Terminating Party
signed by its chief financial officer certifying (A) as to the Inventory
Carrying Costs for the Inventory Supply then on hand and (B) that such Inventory
Carrying Costs have been recorded by the Non-Terminating Party in accordance
with generally accepted accounting principles and in a manner which is
consistent with the Non-Terminating Party's past practice. The Terminating Party
shall pay such Inventory Carrying Costs to the Non-Terminating Party, within
thirty (30) calendar days after its receipt of such certification by the
Non-Terminating Party's chief financial officer. If LifeNet is the
Non-Terminating Party, then LifeNet shall be permitted to distribute the
Inventory Supply and if Osteotech has paid LifeNet LifeNet's Inventory Carrying
Costs in accordance with this Section 6.4.5(a), then LifeNet will pay to
Osteotech the Osteotech Service Fee in accordance with the terms of Section
6.2.1. If Osteotech is the Non-Terminating

                                      E-42
<PAGE>

Party and LifeNet has paid Osteotech its Inventory Carrying Costs in accordance
with this Section 6.4.5(a), then LifeNet shall be permitted to distribute the
Inventory Supply and retain all fees collected therefor (i.e., without payment
of the Osteotech Service Fee or the DePuy Service Fee).

                  (b) In the event the Primary Agreement is terminated by
Osteotech or LifeNet, (the terminating Party defined as the "Terminating Party"
and the other Party defined as the "Non-Terminating Party" for purposes of this
Section 6.4.5(b)) under Section 11.3 (Representations, Warranties and Covenants)
of the Primary Agreement, and there shall be any Inventory Supply remaining
undistributed at the time that the termination becomes effective, then the
Terminating Party shall deliver a statement to the Non-Terminating Party signed
by its chief financial officer certifying (A) as to the Inventory Carrying Costs
for the Inventory Supply then on hand and (B) that such Inventory Carrying Costs
have been recorded by the Terminating Party in accordance with generally
accepted accounting principles and in a manner which is consistent with the
Terminating Party's past practice. The Non-Terminating Party shall pay such
Inventory Carrying Costs to the Terminating Party, within thirty (30) calendar
days after its receipt of such certification by the Terminating Party's chief
financial officer. If LifeNet is the Non-Terminating Party, then LifeNet shall
be permitted to distribute the Inventory Supply and if Osteotech has paid
LifeNet LifeNet's Inventory Carrying Costs in accordance with this Section
6.4.5(b), then LifeNet will pay to Osteotech the Osteotech Service Fee in
accordance with the terms of Section 6.2.1. If Osteotech is the Non-Terminating
Party and LifeNet has paid Osteotech its Inventory Carrying Costs in accordance
with this Section 6.4.5(b), then LifeNet shall be permitted to distribute the
Inventory Supply and retain all fees collected therefor (i.e., without payment
of the Osteotech Service Fee or the DePuy Service Fee).

                  (c) In the event the Primary Agreement is terminated as to
some or all Carrier Allografts due to the actions of Osteotech or LifeNet, under
Section 11.4 (Infringement) of the Primary Agreement, and there shall be any
Inventory Supply remaining undistributed at the time that the termination
becomes effective, then reimbursement for such Inventory Supply will be treated
as follows:

                  (i)   If LifeNet terminates pursuant to the terms of Section
                        11.4.1 of the Primary Agreement and there shall be any
                        Inventory Supply remaining undistributed at the time
                        that the termination becomes effective, then LifeNet
                        shall deliver a statement to Osteotech signed by its
                        chief financial officer certifying (A) as to the
                        Inventory Carrying Costs for the Inventory Supply then
                        on hand and (B) that such Inventory Carrying Costs have
                        been recorded by LifeNet in accordance with generally
                        accepted accounting principles and in a manner which is
                        consistent with LifeNet's past practice. Osteotech shall
                        pay such Inventory Carrying Costs to LifeNet, within
                        thirty (30) calendar days after its receipt of such
                        certification by LifeNet's chief financial officer and
                        LifeNet shall destroy its remaining Inventory Supply.

                                      E-43
<PAGE>

                  (ii)  If Osteotech terminates pursuant to the terms of Section
                        11.4.1 of the Primary Agreement and there shall be any
                        Inventory Supply remaining undistributed at the time
                        that the termination becomes effective, then Osteotech
                        shall deliver a statement to LifeNet signed by its chief
                        financial officer certifying (A) as to the Inventory
                        Carrying Costs for the Inventory Supply then on hand and
                        (B) that such Inventory Carrying Costs have been
                        recorded by Osteotech in accordance with generally
                        accepted accounting principles and in a manner which is
                        consistent with Osteotech' s past practice. LifeNet
                        shall pay such Inventory Carrying Costs to Osteotech,
                        within thirty (30) calendar days after its receipt of
                        such certification by Osteotech's chief financial
                        officer and LifeNet shall destroy its remaining
                        Inventory Supply.

                  (d) In the event the Primary Agreement is terminated by
LifeNet pursuant to Sections 11.7 or 11.8 (Change of Ownership or Control), or
terminated as to Product(s) pursuant to Section 11.10 (Loss of Valid Patent
Claims) of the Primary Agreement, and there shall be any Inventory Supply
remaining undistributed at the time that the termination becomes effective, then
Osteotech shall deliver a statement to LifeNet signed by its chief financial
officer certifying (A) as to the Inventory Carrying Costs for the Inventory
Supply then on hand and (B) that such Inventory Carrying Costs have been
recorded by Osteotech in accordance with generally accepted accounting
principles and in a manner which is consistent with Osteotech' s past practice.
LifeNet shall pay such Inventory Carrying Costs to Osteotech, within thirty (30)
calendar days after its receipt of such certification by Osteotech's chief
financial officer. If LifeNet has paid Osteotech its Inventory Carrying Costs in
accordance with this Section 6.4.5(d), then LifeNet shall be permitted to
distribute the Inventory Supply and retain all fees collected therefor (i.e.,
without payment of the Osteotech Service Fee for the DePuy Service Fee).

                  (e) In the event the Primary Agreement is terminated by
LifeNet pursuant to Section 11.9 (Donor Sources) of the Primary Agreement, and
there shall be any Inventory Supply remaining undistributed at the time that the
termination becomes effective, then LifeNet shall deliver a statement to
Osteotech signed by its chief financial officer certifying (A) as to the
Inventory Carrying Costs for the Inventory Supply then on hand and (B) that such
Inventory Carrying Costs have been recorded by LifeNet in accordance with
generally accepted accounting principles and in a manner which is consistent
with LifeNet's past practice. Osteotech shall pay such Inventory Carrying Costs
to LifeNet, within thirty (30) calendar days after its receipt of such
certification by LifeNet's chief financial officer. If Osteotech has paid
LifeNet its Inventory Carrying Costs in accordance with this Section 6.4.5(e),
then LifeNet shall be permitted to distribute the Inventory Supply and will pay
to Osteotech the Osteotech Service Fee in accordance with the terms of Section
6.2.1.

            6.4.6 Termination under Section 10.4 (Material Breach by LifeNet).
In the event this Agreement is terminated by DePuy or Osteotech pursuant to
Section 10.4 hereof due to LifeNet's material breach of its representations,
warranties or covenants contained in this

                                      E-44
<PAGE>

Agreement, and there shall be any Inventory Supply remaining undistributed at
the time that the termination becomes effective, then Osteotech shall deliver a
statement to LifeNet signed by its chief financial officer certifying (A) as to
the Inventory Carrying Costs for the Inventory Supply then on hand and (B) that
such Inventory Carrying Costs have been recorded by Osteotech in accordance with
generally accepted accounting principles and in a manner which is consistent
with Osteotech' s past practice. LifeNet shall pay such Inventory Carrying Costs
to Osteotech, within thirty (30) calendar days after its receipt of such
certification by Osteotech's chief financial officer. If LifeNet has paid
Osteotech its Inventory Carrying Costs in accordance with this Section 6.4.6,
then LifeNet shall be permitted to distribute the Inventory Supply and retain
all fees collected therefor (i.e., without payment of the Osteotech Service Fee
or the DePuy Service Fee).

            6.4.7 Termination under Section 10.4 (Material Breach by Osteotech).
In the event this Agreement is terminated by DePuy or LifeNet pursuant to
Section 10.4 hereof due to Osteotech's material breach of its representations,
warranties or covenants contained in this Agreement, and there shall be any
Inventory Supply remaining undistributed at the time that the termination
becomes effective, then LifeNet shall deliver a statement to Osteotech signed by
its chief financial officer certifying (A) as to the Inventory Carrying Costs
for the Inventory Supply then on hand and (B) that such Inventory Carrying Costs
have been recorded by LifeNet in accordance with generally accepted accounting
principles and in a manner which is consistent with LifeNet's past practice.
Osteotech shall pay such Inventory Carrying Costs to LifeNet, within thirty (30)
calendar days after its receipt of such certification by LifeNet's chief
financial officer. If Osteotech has paid LifeNet its Inventory Carrying Costs in
accordance with this Section 6.4.7, then LifeNet shall be permitted to
distribute the Inventory Supply and will pay to Osteotech the Osteotech Service
Fee in accordance with the terms of Section 6.2.1.

            6.4.8 Termination under Section 10.5 (Infringement by LifeNet
Technology). In the event this Agreement is terminated as to Product(s) by any
Party pursuant to Section 10.5 hereof related to a lawsuit claiming that the
applicable LifeNet Technology infringes the patents at issue, and there shall be
any Inventory Supply remaining undistributed at the time that the termination
becomes effective, then Osteotech shall deliver a statement to LifeNet signed by
its chief financial officer certifying (A) as to the Inventory Carrying Costs
for the Inventory Supply then on hand and (B) that such Inventory Carrying Costs
have been recorded by Osteotech in accordance with generally accepted accounting
principles and in a manner which is consistent with Osteotech's past practice.
LifeNet shall pay such Inventory Carrying Costs to Osteotech, within thirty (30)
calendar days after its receipt of such certification by Osteotech's chief
financial officer and destroy the remaining Inventory Supply.

            6.4.9 Termination under Section 10.5 (Infringement by Osteotech
Patents). In the event this Agreement is terminated as to Product(s) by any
Party pursuant to Section 10.5 hereof related to a lawsuit claiming that the
applicable one or more of the Osteotech Patents infringe the patents at issue,
and there shall be any Inventory Supply remaining undistributed at the time that
the termination becomes effective, then LifeNet shall deliver a statement to
Osteotech signed by its chief financial officer certifying (A) as to the
Inventory Carrying Costs for the Inventory Supply then on hand and (B) that such
Inventory Carrying Costs have been recorded by LifeNet in accordance with
generally accepted accounting principles and in a manner which is consistent
with LifeNet' s past practice. Osteotech shall pay

                                      E-45
<PAGE>

such Inventory Carrying Costs to LifeNet, within thirty (30) calendar days after
its receipt of such certification by LifeNet's chief financial officer. LifeNet
shall destroy its remaining Inventory Supply.

            6.4.10 Termination under Section 10.6 (Invalidity of Osteotech
Patents). In the event this Agreement is terminated as to Product(s) by any
Party pursuant to Section 10.6, none of the Parties will be entitled to receive
reimbursement for any remaining Inventory Supply and none of the Parties will be
obligated to reimburse any other Party for any remaining Inventory Supply.
Subject to the preceding sentence, LifeNet shall be permitted to distribute the
Inventory Supply and will pay the Osteotech Service Fee, the DePuy Service Fee,
and retain the LifeNet Fee in accordance with the terms of Section 6.2 for any
Products distributed after the effective date of such termination.

            6.4.11 Termination under Section 10.7 (Recall Caused by Osteotech).
In the event this Agreement is terminated as to Product(s) by any Party pursuant
to Section 10.7 and the recall or corrective action that forms the basis for the
right to terminate this Agreement as to such Product(s) is the result of an
action or omission of Osteotech, and there shall be any Inventory Supply
remaining undistributed at the time that the termination becomes effective, then
LifeNet shall deliver a statement to Osteotech signed by its chief financial
officer certifying (A) as to the amount of the Inventory Carrying Costs
reflected by LifeNet on its books and records for the Inventory Supply then on
hand and (B) that such Inventory Carrying Costs have been recorded by LifeNet in
accordance with generally accepted accounting principles and in a manner which
is consistent with LifeNet's past practice. Osteotech shall pay the amount of
such Inventory Carrying Costs to LifeNet, within thirty (30) calendar days after
its receipt of such certification by LifeNet's chief financial officer.

            6.4.12 Termination under Section 10.7 (Recall Caused by LifeNet). In
the event this Agreement is terminated as to Product(s) by any Party pursuant to
Section 10.7 and the recall or corrective action that forms the basis for the
right to terminate this Agreement as to such Product(s) is the result of an
action or omission of LifeNet, and there shall be any Inventory Supply remaining
undistributed at the time that the termination becomes effective, then Osteotech
shall deliver a statement to LifeNet signed by its chief financial officer
certifying (A) as to the amount of the Inventory Carrying Costs reflected by
Osteotech on its books and records for the Inventory Supply then on hand and (B)
that such Inventory Carrying Costs have been recorded by Osteotech in accordance
with generally accepted accounting principles and in a manner which is
consistent with Osteotech's past practice. LifeNet shall pay the amount of such
Inventory Carrying Costs to Osteotech, within thirty (30) calendar days after
its receipt of such certification by Osteotech's chief financial officer.

            6.4.13 Termination under Section 10.8 (Premarket Approval). In the
event this Agreement is terminated pursuant to Section 10.8 and the further
distribution of Product is prohibited as a result of the FDA's final
determination and there shall be any Inventory Supply remaining undistributed at
the time that the termination becomes effective, then LifeNet and Osteotech
shall each deliver a statement to each other and to DePuy signed by their
respective chief financial officers certifying (A) as to the Inventory Carrying
Costs for the Inventory Supply then on hand and (B) that such Inventory Carrying
costs have been recorded by each of LifeNet and Osteotech, as the case may be,
in accordance with generally accepted

                                      E-46
<PAGE>

accounting principles and in a manner which is consistent with each of their
past practices. Each Party will then pay the other Parties, as necessary, based
on each Party's relative Inventory Carrying Costs, so that each of Osteotech,
LifeNet, and DePuy, shall bear equally one-third (1/3) of the Inventory Carrying
Costs of the remaining Inventory Supply. In the event this Agreement is
terminated pursuant to Section 10.8 and the further distribution of Product is
permitted for a period of time shorter than the Carry-Over Period (the "FDA
CARRY-OVER PERIOD") under the FDA's final determination and there shall be any
Inventory Supply remaining undistributed at the time that the termination
becomes effective, then DePuy shall have the right during the shorter of the
Carry-Over Period or the FDA Carry-Over Period to continue to promote the
Products in order to allow for the distribution of the Inventory Supply. If
there shall be any Inventory Supply remaining undistributed at the end of the
Carry-Over Period, as modified, the Parties will provide to one another the
certifications described in the first sentence of this paragraph and reimburse
one another as described in the second sentence of this paragraph so that each
of Osteotech, LifeNet, and DePuy, shall bear equally one-third (1/3) of the
Inventory Carrying Costs of the remaining Inventory Supply.

            6.4.14 Termination under Section 10.11 (DBM Notice of Sale). In the
event this Agreement is terminated by Osteotech or LifeNet (the terminating
Party defined as the "Terminating Party" and the other Party defined as the
"Non-Terminating Party" for purposes of this Section 6.4.14) pursuant to Section
10.11, and there shall be any Inventory Supply remaining undistributed at the
time that the termination becomes effective, then the Non-Terminating Party
shall deliver a statement to the Terminating Party signed by its chief financial
officer certifying (A) as to the Inventory Carrying Costs for the Inventory
Supply then on hand and (B) that such Inventory Carrying Costs have been
recorded by the Non-Terminating Party in accordance with generally accepted
accounting principles and in a manner which is consistent with the
Non-Terminating Party's past practice. The Terminating Party shall pay such
Inventory Carrying Costs to the Non-Terminating Party, within thirty (30)
calendar days after its receipt of such certification by the Non-Terminating
Party's chief financial officer.

      6.5 Product Development Payment. Without limiting the provisions of
Section 6 hereof, DePuy shall pay to Osteotech within three Business Days after
the Effective Date the Product Development Payment in consideration of
Osteotech's efforts to develop the Products described in EXHIBIT A. The Product
Development Payment shall not be refundable by Osteotech regardless of whether
such Products are successfully developed and/or become subject to this
Agreement. The Product Development Payment shall not cover the development of
any products other than those Products described in EXHIBIT A ***.

SECTION 7 REPORTS, ETC.

      7.1 Monthly Reports. To facilitate the payments due from Osteotech to
DePuy pursuant to this Agreement, LifeNet will provide to Osteotech and DePuy
the Section 7.1 Report within five (5) Business Days after the end of each
calendar month. All information

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-47
<PAGE>

contained in each Section 7.1 Report shall be Confidential Information of
LifeNet and Osteotech and DePuy each agrees that only its respective employees
who have a need to know such information will have access to the Section 7.1
Reports it receives from LifeNet; provided that no employees of Osteotech in its
sales or marketing departments shall have access to such reports.

      7.2 Quarterly Reports. Within fifteen (15) Business Days after the last
calendar day of each calendar quarter, DePuy shall deliver to Osteotech a
Section 7.2 Report.

      7.3 Taxes. Each Party shall be responsible for its own tax compliance and
payments regarding its activities under this Agreement.

      7.4 Audit Rights.

            7.4.1 Section 7.2 Reports. DePuy agrees to keep, for a period of
three (3) years after delivery of each of the Section 7.2 Reports, true and
accurate records of the data utilized for the purpose of preparing the Section
7.2 Reports and such records shall contain sufficient detail to permit a
determination of the accuracy of the Section 7.2 Reports. Osteotech shall have
the right during the applicable three (3) year period after the delivery of each
Section 7.2 Report, at its own expense and upon reasonable notice, to cause an
Auditor consented to by DePuy (whose consent thereto shall not be unreasonably
withheld) to conduct an audit of all of the relevant records of DePuy required
for the preparation of such Section 7.2 Report in order to determine and prepare
the Audit Report regarding the accuracy of such Section 7.2 Report. Such Auditor
shall deliver the Audit Report to each of Osteotech and DePuy. The Audit Report
will merely state whether the Section 7.2 Report was accurate and if the Section
7.2 Report was not accurate, the Audit Report will set forth the correct
information that should have been reported in the Section 7.2 Report. No more
than one such audit shall be conducted each Contract Year, provided that any
Section 7.2 Report not previously audited may be audited in a subsequent audit.
Any such audit shall be conducted upon reasonable notice to DePuy and within
normal business hours of DePuy and shall be carried out in a manner which shall
not materially interfere with DePuy's business or operations. The Audit Report
shall be treated by Osteotech as Confidential Information. If the Audit Report
confirms that the amount invoiced for DBM Carrier Products, which are not
Products under this Agreement and are marketed, promoted or sold by DePuy and
its DBM Promoting Affiliates, is more than five percent (5%) different than the
amount reported on the Section 7.2 Report, and such difference is not
attributable to untimely, inaccurate or incomplete information received by DePuy
from third parties (e.g., LifeNet), DePuy shall reimburse Osteotech for the
costs of such audit.

            7.4.2 Osteotech Suggested End User Fees. LifeNet will have the right
to cause, at its own expense, an Auditor, consented to by Osteotech (whose
consent thereto shall not be unreasonably withheld), to conduct an audit to
verify Osteotech's compliance with the terms of Section 6.1.1(a). Osteotech may
require that such an Auditor execute a confidentiality agreement with regard to
the information accessed for such audit. Any such audit shall be conducted upon
reasonable notice to Osteotech, within the normal business hours of Osteotech,
and shall be carried out in a manner which shall not materially interfere with
Osteotech's business or operations. The Auditor shall produce and deliver a
certificate as to whether Osteotech is in compliance with Section 6.1.1(a), and
in the event Osteotech is not in

                                      E-48
<PAGE>

compliance, the Auditor will specify how the Osteotech Suggested End User Fee
must be adjusted in order for Osteotech to comply with the terms of Section
6.1.1(a). No more than one such audit shall be conducted in each Contract Year.

            7.4.3 Inventory Supply and Reimbursements. In the event of
reimbursement between any of the Parties pursuant to Section 6.4 hereof, the
Party paying the reimbursement will have the right to cause, at its own expense,
an Auditor, consented to by the Party to be reimbursed (whose consent thereto
shall not be unreasonably withheld), to conduct an audit of all of the relevant
records required for the calculation of such reimbursement amount. Any such
audit shall be conducted upon reasonable notice to the Party being audited,
within the normal business hours of the Party being audited, and shall be
carried out in a manner which shall not materially interfere with such Party's
business or operations. In the event that such an audit is requested, the date
of payment for such reimbursement shall be delayed by up to thirty (30) calendar
days.

SECTION 8 INDEMNIFICATION

      8.1 Intellectual Property Indemnification by Osteotech. Osteotech (as the
indemnifying Party) agrees to defend, hold harmless and indemnify DePuy and/or
LifeNet, as the case may be, (and their respective Affiliates, officers,
directors, employees, and promotional agents retained pursuant to this
Agreement) against any and all Losses for patent infringement resulting from the
use of the Osteotech Patents for the processing, promotion or distribution of
Products pursuant to this Agreement or for any trademark or trade secret
infringement caused by the use of any Trademark or trade secret of Osteotech
utilized pursuant to this Agreement; provided, however, such indemnification
shall not be required to the extent that such Losses are proximately caused by
(i) the negligence or intentional wrongful acts of the Party seeking
indemnification, (ii) the use of LifeNet Technology or LifeNet Trademarks or
trade secrets of LifeNet as permitted in this Agreement, or (iii) any
modification of any Products by DePuy or LifeNet, as the case may be, not
approved by Osteotech in writing.

      8.2 Promotional Material Indemnification by Osteotech. Osteotech (as the
indemnifying Party) agrees to defend, hold harmless and indemnify DePuy and/or
LifeNet, as the case may be, (and their respective Affiliates, officers,
directors, employees, and promotional agents retained pursuant to this
Agreement) against any and all Losses based upon or arising out of the use of
any Promotional Materials, to the extent any such Losses are based upon
information or data provided by Osteotech pursuant to Section 5.4.2.

      8.3 General Indemnification by Osteotech. Osteotech (as the indemnifying
Party) agrees to defend, hold harmless and indemnify DePuy and/or LifeNet, as
the case may be (and their respective Affiliates, officers, directors,
employees, and promotional agents retained pursuant to this Agreement), against
any and all Losses arising from (i) a breach or default by Osteotech of any of
its representations, warranties or covenants contained in this Agreement, (ii) a
defect in any finished unit of tissue processed by Osteotech into Product or
from a failure of workmanship by Osteotech, except to the extent such defect is
caused by or results from any action or omission for which LifeNet is required
to indemnify Osteotech and DePuy pursuant to Section 8.6(ii) hereof, or (iii)
any representation made by any employee or authorized agent of

                                      E-49
<PAGE>

Osteotech regarding any Product processed by Osteotech pursuant to this
Agreement which is false or misleading.

      8.4 Intellectual Property Indemnification by LifeNet. LifeNet (as the
indemnifying Party) agrees to defend, hold harmless, and indemnify DePuy and/or
Osteotech, as the case may be, (and their respective Affiliates, officers,
directors, employees, and promotional agents retained pursuant to this
Agreement) against any and all Losses for intellectual property infringement
resulting from the use of LifeNet Technology, LifeNet Trademarks, or LifeNet
trade secrets in accordance with the terms of this Agreement; provided, however,
such indemnification shall not be required to the extent that such Losses are
proximately caused by (i) the negligence or intentional wrongful acts of the
Party seeking indemnification, (ii) use of the Osteotech Patents or the use of
any Trademark or trade secret of Osteotech as permitted under the terms of this
Agreement, or (iii) any modification of any Products by DePuy or Osteotech, as
the case may be, not approved by LifeNet in writing.

      8.5 Promotional Material Indemnification by LifeNet. LifeNet (as the
indemnifying Party) agrees to defend, hold harmless and indemnify Osteotech (and
its respective Affiliates, officers, directors, and employees) against any and
all Losses regarding any Promotional Materials LifeNet and/or DePuy prepares,
approves, and/or uses, except to the extent that any such dispute or lawsuit is
based on information or data provided by Osteotech pursuant to Section 5.4.2
hereof.

      8.6 General Indemnification by LifeNet. LifeNet (as the indemnifying
Party) agrees to defend, hold harmless, and indemnify DePuy and/or Osteotech, as
the case may be, (and their respective Affiliates, officers, directors,
employees, and promotional agents retained pursuant to this Agreement) against
any and all Losses arising from (i) a breach or default by LifeNet of any of its
representations, warranties or covenants contained in this Agreement; (ii) a
defect in any unit of tissue (a) recovered and/or processed by LifeNet under
this Agreement to the extent such defect results from an error or omission by
LifeNet (including any employee or agent of LifeNet), or from a failure of
workmanship by LifeNet or, (b) resulting from tissue recovery, processing,
and/or distribution activities performed by LifeNet (including any employee or
agent of LifeNet) pursuant to this Agreement, including without any limitation
any testing performed by or at the direction of LifeNet; or (iii) a
representation made by any employee or authorized agent of LifeNet regarding any
Product processed by Osteotech which is provided to LifeNet pursuant to this
Agreement which is false or misleading.

      8.7 Indemnification by DePuy. DePuy (as the indemnifying Party) agrees to
defend, hold harmless and indemnify Osteotech and/or LifeNet, as the case may be
(and their respective Affiliates, officers, directors, and employees), against
any and all Losses arising from (i) a breach or default by DePuy of any of its
representations, warranties or covenants contained in this Agreement or (ii) any
representation made by any employee or authorized agent of DePuy regarding any
Product promoted by DePuy pursuant to this Agreement which is false or
misleading and inconsistent with the Promotional Materials. DePuy shall have no
liability hereunder for any promotional activity conducted by or on behalf of
DePuy if such liability is based upon or arises from the failure of Osteotech or
LifeNet to make appropriate regulatory submissions or to comply with regulatory
requirements relating to the distribution of any of the Products.

                                      E-50
<PAGE>

      8.8 Conditions to Indemnifications. The obligations and liabilities of the
indemnifying Party hereunder with respect to claims resulting from the assertion
of liability by third parties shall be subject to the following terms and
conditions:

            8.8.1 Written Notice by Indemnified Party. The indemnified Party
shall give written notice to the indemnifying Party of any assertion of claim by
a third party which might give rise to a claim by the indemnified Party against
the indemnifying Party based on the indemnity contained herein, stating the
nature and basis of said assertion and the amount thereof, to the extent known,
within five (5) Business Days after an officer of the indemnified Party learns
of the claim or receives notice thereof. Failure to give such notice within five
(5) Business Days may, at the indemnifying Party's option result in a reduction
in any subsequent indemnification payment by an amount equivalent to the
expenses and/or losses demonstrated by the indemnifying Party to have been
caused by such delay in notification.

            8.8.2 Indemnifying Party Right To Defend. In the event any action,
suit or proceeding is brought against the indemnified Party, with respect to
which the indemnifying Party may have liability under the indemnity agreement
contained herein, the action, suit or proceeding shall, upon the written request
of the indemnified Party and the written agreement of the indemnifying Party
that it is obligated to indemnify under the indemnity agreement contained
herein, be defended (including all proceedings on appeal or for review which
counsel for the defendant shall deem appropriate) by the indemnifying Party. The
indemnified Party shall have the right to be represented by advisory counsel and
accountants, at its own expense, and shall be kept fully informed of such
action, suit or proceeding at all stages thereof, whether or not it is so
represented. The indemnifying Party shall make available to the indemnified
Party and its attorneys and accountants all books and records of the
indemnifying Party relating to such action, suit or proceeding. The Parties will
render reasonable assistance to each other in order to ensure the proper and
adequate defense of any such action, suit or proceeding.

            8.8.3 Consent of Indemnified Party Required for Settlement. The
indemnifying Party shall not make any settlement of any claims that are the
subject of a claim of indemnification without the written consent of the
indemnified Party, which consent shall not be unreasonably withheld or delayed.

            8.8.4 Consent of Indemnifying Party Required for Settlement. The
indemnified Party shall not make any settlement of any claims that are the
subject of a claim for indemnification without the written consent of the
indemnifying Party.

      8.9 Insurance. So long as available on commercially reasonable terms, each
of the Parties agrees to procure and maintain at its respective cost and expense
in full force and effect during the term of this Agreement and for at least five
(5) years thereafter valid and collectible insurance policies in connection with
its activities as contemplated hereby, which policies shall provide coverage for
product liability relating to use of the Products in an amount *** and for
professional liability and comprehensive general liability in an amount ***.

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-51
<PAGE>

All such insurance shall be primary over any insurance maintained by each of the
Parties. The product liability and general liability policies (but not the
professional liability policy) shall name each of the other Parties as an
additional insured; provided that this requirement as applied to DePuy shall not
apply with regard to DePuy's product liability policy. Upon a Party's request,
each Party shall provide to such requesting Party a certificate of coverage or
other written evidence reasonably satisfactory to such requesting Party of such
insurance coverage. In the event a Party is unable to maintain the insurance in
accordance with the terms of this Section 8.9, such Party shall promptly notify
the other Parties in writing. Such insurance policy shall provide that in the
event such insurance coverage should be materially adversely changed or
terminated for any reason, the insurer thereunder will give each of the other
Parties thirty (30) calendar days' prior written notice. The existence of such
coverage shall in no way limit any of the Parties' liabilities or obligations
hereunder.

      8.10 LIMITATION ON LIABILITY. EXCEPT FOR EACH PARTY'S INDEMNIFICATION
OBLIGATIONS UNDER THIS AGREEMENT, IN NO EVENT SHALL ANY PARTY, ITS DIRECTORS,
OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO ANY OTHER PARTY FOR ANY
PUNITIVE, SPECIAL, INCIDENTAL, INDIRECT, CONSEQUENTIAL, EXEMPLARY OR TORT
DAMAGES INCLUDING ANY DAMAGES RESULTING FROM LOST PROFITS OR LOSS OF BUSINESS,
WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT
LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT, AND EACH
PARTY HEREBY WAIVES ANY RIGHT TO SEEK SUCH DAMAGES.

SECTION 9 CONFIDENTIALITY

      9.1 Generally. In order to facilitate this Agreement it will be necessary
for the Parties to exchange certain Confidential Information. Each Party agrees
to retain the Confidential Information of the other Parties in strict confidence
and not to disclose or transfer the Confidential Information to any Person or
use the Confidential Information other than as expressly authorized by the terms
of this Agreement or otherwise in writing by the disclosing Party. All
Confidential Information shall remain the property of the disclosing Party, and
no copies thereof shall be made without the prior written consent of the
disclosing Party (except for distribution to employees and agents of the
receiving Party who have a need to know such information to carry out the
receiving Party's obligations under this Agreement), and all such copies shall,
at the request of the disclosing Party, either be destroyed or returned by the
receiving Party to the disclosing Party and any extracts, summaries or portions
thereof used for other purposes and any other documents or materials containing
any thereof shall be destroyed by the receiving Party. The Parties acknowledge
that such Confidential Information can constitute "inside information" for
securities purposes and the responsibility to refrain from any unauthorized
disclosure, trading or other such improper use. Each Party represents to the
other that it maintains policies and procedures designed to prevent unauthorized
disclosure of its own Confidential Information. All employees of a Party
performing services under this Agreement that have access to the Confidential
Information shall be subject to agreements prohibiting the disclosure of
Confidential Information

                                      E-52
<PAGE>

      9.2 Obligations on Termination. Upon the termination of this Agreement for
any reason, each Party shall, as promptly as is practicable (but in no event
more than thirty (30) calendar days after the termination of this Agreement),
return to the Party from whom it was received, free of charge, or certify
destruction of, all materials containing Confidential Information of the
disclosing Party then in its possession or in the possession of its employees or
agents, and shall cease from making further use of any such materials.

SECTION 10 TERM

      10.1 Generally. This Agreement shall commence and become effective as of
the Effective Date and, unless sooner terminated pursuant to provisions herein,
shall continue in force for a period of five (5) Contract Years. Notwithstanding
that the Effective Date commences as of January 1, 2003, once executed by all of
the Parties, this Agreement may not be terminated or modified prior to the
Effective Date. Thereafter, this Agreement shall automatically renew for
successive one (1) year periods, unless or until any Party shall have given the
other Parties written notice of termination of this Agreement at least one
hundred twenty (120) calendar days prior to the expiration of the then
current-term. Notwithstanding the terms of this Section 10.1, Osteotech may not
provide the notice of termination described in the preceding sentence until the
seventh Contract Year (such notice of termination not to become effective until
the end of the seventh Contact Year). In the event that a notice of termination
is provided by DePuy pursuant to the terms of this Section 10.1, then this
Agreement will terminate only as to DePuy upon the effective date of such
termination, and each of Osteotech and LifeNet may waive such termination as to
each other in accordance with the terms of Section 10.15 hereof.

      10.2 Termination of Primary Agreement. Notwithstanding anything to the
contrary contained herein, this Agreement will terminate in the event the
Primary Agreement is terminated as to all of the Products produced under this
Agreement. Osteotech shall promptly provide DePuy with written notice of any
termination of the Primary Agreement.

      10.3 Bankruptcy. This Agreement may be terminated by a Party upon one
hundred twenty (120) calendar days' written notice if any other Party files a
voluntary petition for bankruptcy or reorganization, is the subject of an
involuntary petition for bankruptcy which is not dismissed within thirty (30)
calendar days, has its affairs placed in the hands of a receiver, enters into a
composition for the benefit of creditors, or is deemed insolvent by a court of
competent jurisdiction. In the event that (a) a notice of termination is
provided by DePuy pursuant to the terms of this Section 10.3 or (b) either of
LifeNet or Osteotech provides a notice of termination pursuant to the terms of
this Section 10.3 due to DePuy's bankruptcy, insolvency, or receivership as set
forth in this Section 10.3, then this Agreement will terminate only as to DePuy
upon the effective date of such termination, and each of Osteotech and LifeNet
may waive such termination as to each other in accordance with the terms of
Section 10.15 hereof.

      10.4 Material Breach of Representations, Warranties, or Covenants. This
Agreement may be terminated by a Party if any other Party is in material breach
of its representations, warranties, or covenants contained in this Agreement;
provided that such non-breaching Party has provided at least thirty (30)
calendar days' prior written notice to the breaching Party (and a copy to the
other Parties) identifying the breach and such breach has not

                                      E-53
<PAGE>

been cured within such thirty (30) calendar day period after receipt of notice
thereof. In the event that (a) a notice of termination is provided by DePuy
pursuant to the terms of this Section 10.4, or (b) either of LifeNet or
Osteotech provides a notice of termination pursuant to the terms of this Section
10.4 due to DePuy's material breach of DePuy's representations, warranties, or
covenants, then this Agreement will terminate only as to DePuy upon the
effective date of such termination, and each of Osteotech and LifeNet may waive
such termination as to each other in accordance with the terms of Section 10.15
hereof.

      10.5 Infringement. If any Party is served as a party to a lawsuit filed by
a third party alleging that any Product infringes any claim of any U.S. patent
or reissues or reexaminations thereof, such Party may, in its sole discretion,
terminate this Agreement as to the Product which is the subject to such third
party lawsuit upon thirty (30) calendar days' prior written notice to the other
Parties and this Agreement shall continue with respect to all other Products
which are not subject to such infringement lawsuit by a third party. For
purposes of this Section 10.5, none of the Parties or any of their respective
Affiliates shall be deemed to be a third party. In the event that DePuy provides
a notice of termination as to the Product that is the subject of such a lawsuit
pursuant to the terms of this Section 10.5, then this Agreement will terminate
as to such Product only as to DePuy upon the effective date of such termination,
and each of Osteotech and LifeNet may waive such termination as to each other in
accordance with the terms of Section 10.15 hereof.

      10.6 Invalidity of Osteotech Patents. During the term of this Agreement,
in the event that the claims of any of the Osteotech Patents should be
determined to be invalid by a court of law or the U.S. Patent and Trademark
Office in a non-appealable final judgment with the result that there are no
claims of any Osteotech Patents that cover a particular Product, then Osteotech
agrees that each of DePuy or LifeNet may, at its sole option, terminate this
Agreement immediately on written notice to Osteotech solely as to the Product(s)
no longer covered by any Osteotech Patent claims, provided that this Agreement
shall remain in effect with respect to any Products covered by remaining claims
of Osteotech Patents. In response to any such notice of termination, Osteotech
may call to the attention of the Party sending such notice claims of Osteotech
Patents that cover such Product(s). In the event a termination based on claim
invalidation becomes effective as to any Product as provided in this Section
10.6, such Product shall no longer be within the range of any provisions in this
Agreement providing exclusivity to, or by, DePuy or LifeNet. In the event that
DePuy provides a notice of termination as to the Product that is the subject of
such a non-appealable final judgment pursuant to the terms of this Section 10.6,
then this Agreement will terminate as to such Product only as to DePuy upon the
effective date of such termination, and each of Osteotech and LifeNet may waive
such termination as to each other in accordance with the terms of Section 10.15
hereof.

      10.7 Recall or Corrective Action. If any of the Products is subject to a
product recall, any Party may, except as provided in the next sentence,
terminate this Agreement as to the Product which is subject to such recall upon
thirty (30) calendar days' prior written notice to the other Parties and this
Agreement shall continue with respect to all other Products which are not
subject to such recall. Except as provided in the next sentence, none of the
Parties shall have the right to terminate this Agreement as a result of any
corrective action which does not also involve a recall. If a corrective action
results in the cessation of sale of one or more Products for a period exceeding
forty-five (45) calendar days, DePuy may terminate this Agreement upon thirty
(30)

                                      E-54
<PAGE>

calendar days' prior written notice to Osteotech and LifeNet as to the Product
or Products which are the subject of such cessation of sale, and this Agreement
shall continue as to all other Products which are not subject to such cessation
of sale. DePuy must exercise its right of termination under this Section 10.7
during the one hundred twenty (120) calendar day period after any such recall is
commenced and DePuy receives notice of such recall. In the event that DePuy
provides a notice of termination as to the Product that is the subject of such a
recall or qualifying corrective action pursuant to the terms of this Section
10.7, then this Agreement will terminate as to such Product only as to DePuy
upon the effective date of such termination, and each of Osteotech and LifeNet
may waive such termination as to each other in accordance with the terms of
Section 10.15 hereof.

      10.8 Premarket Approval (PMA). In the event the FDA should make a final
determination that a Product produced under this Agreement should require the
submission of a Premarket Approval (PMA), the Parties shall meet during the
succeeding ninety (90) calendar days to review the terms of this Agreement, and
the Parties' respective obligations and responsibilities hereunder. If the
Parties are unable to agree to continue this Agreement, this Agreement will
terminate at the end of such ninety (90) calendar day period.

      10.9 Change in Control of Osteotech. DePuy and LifeNet shall each have the
right to terminate this Agreement in its entirety in the event a Person or group
of Persons (as determined under Section 13(d) of the Securities Exchange Act of
1934, as amended, and the regulations promulgated thereunder) acquire more than
fifty per cent (50%) of the outstanding voting stock of Osteotech. DePuy or
LifeNet, as the case may be, must exercise such right of termination within
sixty (60) calendar days after the public announcement of any such change in
control of Osteotech and by providing Osteotech with one hundred twenty (120)
calendar days' prior written notice of such termination. In the event that DePuy
provides a notice of termination pursuant to the terms of this Section 10.9,
then this Agreement will terminate only as to DePuy upon the effective date of
such termination, and each of Osteotech and LifeNet may waive such termination
as to each other in accordance with the terms of Section 10.15 hereof.

      10.10 Osteotech Relationship with RTI or Medtronic. In the event that
Osteotech (or one of its Affiliates) establishes a relationship with either
Regeneration Technologies or Medtronic Sofamor Danek (or any Affiliate of those
two organizations), involving the transfer and/or processing of any allograft
tissue, then each of DePuy or LifeNet shall have the right to terminate this
Agreement upon one hundred twenty (120) calendar days' written notice to
Osteotech. In the event that DePuy provides a notice of termination pursuant to
the terms of this Section 10.10, then this Agreement will terminate only as to
DePuy upon the effective date of such termination, and each of Osteotech and
LifeNet may waive such termination as to each other in accordance with the terms
of Section 10.15 hereof.

      10.11 DBM Notice of Sale. After its receipt of a DBM Notice of Sale,
Osteotech and LifeNet, as the case may be, shall have the right, exercisable
within ninety (90) calendar days after its receipt of such DBM Notice of Sale,
to terminate this Agreement by delivering to DePuy, Osteotech and LifeNet, as
the case may be a nine (9)-month advance written notice. In the event that
either of LifeNet or Osteotech provides a notice of termination pursuant to the
terms of this Section 10.11, then this Agreement will terminate only as to DePuy

                                      E-55
<PAGE>

upon the effective date of such termination, and each of Osteotech and LifeNet
may waive such termination as to each other in accordance with the terms of
Section 10.15 hereof.

      10.12 Distribution of Other DBM Carrier Products by DePuy. If during a
calendar quarter, the aggregate dollar amount (for purposes hereof determined in
U.S. Dollars) invoiced for DBM Carrier Products which are not Products covered
by this Agreement and are promoted or distributed by DePuy and its DBM Promoting
Affiliates is greater than *** of the aggregate dollar amount invoiced during
such quarter for all DBM Carrier Products promoted or distributed by DePuy and
its DBM Promoting Affiliates during such calendar quarter, DePuy will have ***
(the "REMEDY PERIOD") to remedy the situation and cause the aggregate dollar
amount invoiced for Products covered by this Agreement in a calendar quarter to
equal at least *** of the aggregate dollar amount invoiced for all DBM Carrier
Products promoted or distributed by DePuy and its DBM Promoting Affiliates
during such calendar quarter. For purposes of determining the aggregate dollar
amount invoiced for DBM Carrier Products by DePuy and its DBM Promoting
Affiliates in this Section 10.12 and Section 10.14 hereof and otherwise
hereunder, only those DBM Carrier Products promoted or distributed in the
Territory for the Field will be considered.

      10.13 Bone Morphogenic Proteins Exclusion. It is understood and agreed
that the determination under Section 10.12 hereof, of the amount invoiced by
DePuy and its DBM Promoting Affiliates for DBM Carrier Products, shall be based
solely on the amount invoiced for such DBM Carrier Products, excluding any
additional related charges such as for taxes, delivery or other products that
may be combined or delivered with such DBM Carrier Products, and the amount so
invoiced expressed in U.S. dollars, provided that in the event DePuy begins
distributing a DBM Carrier Product that contains or is combined with BMPs such
determination with respect to such DBM Carrier Products that contain or are
combined with BMPs shall be made in U.S. dollars, excluding however that portion
of the price of such DBM Carrier Products which is attributable to the BMPs
contained in such product.

      10.14 Corrective Payments by DePuy.

            10.14.1 Generally. At the midpoint of the *** Remedy Period, if the
aggregate dollar amount invoiced for Products covered by this Agreement during
the preceding *** remains less than ***, but greater than ***, of the aggregate
dollar amount invoiced for all DBM Carrier Products promoted or distributed by
DePuy and its DBM Promoting Affiliates during such *** period, then unless DePuy
pays to Osteotech, within *** after the date of such midpoint, an amount (the
"CORRECTIVE PAYMENT") equal to *** of the dollar amount which would cause the
aggregate dollar amount invoiced for Products covered by this Agreement to be at
such *** level during such *** period, Osteotech may thereafter, in its sole
discretion by delivery of written notice to DePuy terminate during the
applicable Remedy Period this Agreement on ten

----------
*** Indicates the omission of confidential material pursuant to the request for
confidential treatment made in accordance with Rule 24b-2 under the Securities
Exchange Act of 1934, as amended. The confidential material is being filed
separately with the Securities and Exchange Commission.

*** Indicates the omission of confidential material pursuant to the request for
confidential treatment made in accordance with Rule 24b-2 under the Securities
Exchange Act of 1934, as amended. The confidential material is being filed
separately with the Securities and Exchange Commission.

                                      E-56
<PAGE>

(10) calendar days' notice. In the event that Osteotech provides a notice of
termination pursuant to the terms of this Section 10.14.1, then this Agreement
will terminate only as to DePuy upon the effective date of such termination, and
each of Osteotech and LifeNet may waive such termination as to each other in
accordance with the terms of Section 10.15 hereof.

            10.14.2 Midpoint Measurement. At the midpoint of the Remedy Period,
if the aggregate dollar amount invoiced for Products covered by this Agreement
during the preceding *** is not at least *** of the aggregate dollar amount
invoiced for all DBM Carrier Products promoted or distributed by DePuy and its
DBM Promoting Affiliates during such *** period, then DePuy shall be required to
provide Osteotech with a monthly certification of the aggregate dollar amount
invoiced monthly during the subsequent *** period for Products covered by this
Agreement and the aggregate dollar amount invoiced monthly during such
subsequent *** period for all such DBM Carrier Products. Such certification
shall be delivered to Osteotech within fifteen (15) calendar days after the end
of the month being reported upon.

            10.14.3 *** Requirement. If during the *** after the Remedy Period
or during any month reported upon pursuant to Section 10.14.2, the aggregate
amount invoiced for Products covered by this Agreement is not greater than ***
of the aggregate dollar amount invoiced for all DBM Carrier Products promoted or
distributed during such period by DePuy and its DBM Promoting Affiliates, then
Osteotech may terminate during the one hundred twenty (120) calendar day period
after the end of the applicable Remedy Period this Agreement upon ten (10)
calendar days' written notice to DePuy. In the event that Osteotech provides a
notice of termination pursuant to the terms of this Section 10.14.3, then this
Agreement will terminate only as to DePuy upon the effective date of such
termination, and each of Osteotech and LifeNet may waive such termination as to
each other in accordance with the terms of Section 10.15 hereof.

            10.14.4 *** Requirement. If the aggregate dollar amount invoiced
during the entire Remedy Period for Products covered by this Agreement is not at
least *** of the aggregate dollar amount invoiced for all DBM Carrier Products
promoted or distributed by DePuy and its DBM Promoting Affiliates during the
Remedy Period, then Osteotech may terminate this Agreement on thirty (30)
calendar days' prior written notice to DePuy given at any time within sixty (60)
calendar days after the end of the Remedy Period. In the event that Osteotech
provides a notice of termination pursuant to the terms of this Section 10.14.4,
then this Agreement will terminate only as to DePuy upon the effective date of
such termination, and each of Osteotech and LifeNet may waive such termination
as to each other in accordance with the terms of Section 10.15 hereof.

            10.14.5 Certain Exclusions. In the event the aggregate dollar amount
invoiced for Products covered by this Agreement fails to equal at least *** of
the aggregate dollar amount invoiced for all DBM Carrier Products promoted or
distributed by DePuy and its DBM Promoting Affiliates during a calendar quarter
due to a failure of Osteotech

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-57
<PAGE>

to supply sufficient Product (provided that LifeNet has provided Osteotech with
sufficient Allograft Bone Tissue to meet the relevant sales forecast) or due to
a regulatory prohibition or restriction which limits DePuy's ability to promote
the Products, the Remedy Period shall be extended by one calendar quarter for
each calendar quarter during which DePuy fails to meet such requirement due to
such supply or regulatory problem. The foregoing provision extending the Remedy
Period shall not apply during the first year after the Effective Date, shall not
apply with respect to a new Product during the first year after such new Product
is introduced and shall not apply if the amount of Product required to be
supplied by Osteotech is more than 108% of the sales for such Product forecast
by DePuy pursuant to Section 5.3.5 hereof.

      10.15 Osteotech and LifeNet Right to Waive Termination. Except as
otherwise provided in Sections 6.4.2(c) and 6.4.2(d) hereof, in the event of any
termination of this Agreement as to DePuy, LifeNet and Osteotech may jointly
agree to continue all activities related to the Products in accordance with the
terms of this Agreement. In the event that Osteotech and LifeNet elect not to
waive such termination as to each other, then this Agreement will terminate, or
terminate as to Product(s), as the case may be, in accordance with the terms of
the section of this Agreement pursuant to which such notice of termination as to
DePuy was originally given.

      10.16 Effect of Certain Terminations on DePuy Thresholds. In the event
that terminations as to Product(s) under Sections 10.5 (Infringement), 10.6
(Invalidity of Osteotech Patents), or 10.7 (Recall or Corrective Action) hereof
or any other event, other than an event that is the result of DePuy's act or
omission, affects the quantity of Products available to DePuy for promotion of
the Products under the terms of this Agreement, the Parties agree to evaluate
the affected provisions (specifically Sections 1.27, 1.54, 10.12, 10.14, and
EXHIBIT I) and to negotiate in good faith with regard to any adjustment to such
provisions, in order to further the intent of the Parties under this Agreement.

      10.17 Survival. The following Sections of this Agreement shall survive any
termination hereof: Section 1 (Definitions), Section 2.2 (Processing of
Allograft Bone Tissue by Osteotech), Section 2.6 (Covenant Not to Sue), Section
4.1 (Relationship of the Parties),Section 6 (Compensation) to the extent
applicable during any Carry-Over Period or FDA Carry-Over Period, Section 8
(Indemnification), Section 9 (Confidentiality), Section 10 (Term) to the extent
applicable during any Carry-Over Period or FDA Carry-Over Period, Section 10.15
(Osteotech and LifeNet Right to Waive Termination), Section 10.17 (Survival),
Section 12 (Dispute Resolution) and Section 13 (Miscellaneous).

SECTION 11 TRADEMARKS, TRADENAMES, AND PATENTS

      11.1 Generally. Each Product will bear Trademarks pertaining to the name
of the Product and the trade dress of LifeNet. Except as otherwise provided in
EXHIBIT D, the Trademarks pertaining to the Products, included in EXHIBIT D
hereto, shall be determined and owned exclusively by LifeNet.

      11.2 Restriction on Use. Trademarks that are owned by LifeNet and used in
connection with any Product shall be used by DePuy and Osteotech only with
reference to such

                                      E-58
<PAGE>

Product. Notwithstanding the foregoing, neither DePuy nor Osteotech shall use
any Trademark owned by LifeNet in connection with any Product without the prior
written consent of LifeNet.

      11.3 Infringement of Trademarks. Each Party shall advise the other Parties
promptly upon its becoming aware of any infringement by a third party of
Trademarks identifying any Product in the Territory. If warranted in the opinion
of LifeNet, LifeNet shall promptly take such legal action as is required to
restrain or otherwise prevent such infringement. The other Parties shall
cooperate fully with and as requested by LifeNet, at LifeNet's expense, in
LifeNet's attempt to restrain such infringement. LifeNet shall have the sole
right to control the suit or proceeding, including the right to conclude a
settlement on terms and conditions it deems fit, provided that LifeNet may not
obligate any other Party (whether monetarily or otherwise) as part of any such
settlement without the prior written consent of such other Party.

      11.4 Infringement of Osteotech Patents. Each Party shall advise the other
Parties promptly upon its becoming aware of any infringement by a third party of
Osteotech Patents affecting any Product in the Territory. If warranted in the
opinion of Osteotech, Osteotech shall promptly take such legal action as is
required to restrain or otherwise prevent such infringement. The other Parties
shall cooperate fully with and as requested by Osteotech, at Osteotech's
expense, in Osteotech's attempt to restrain such infringement. Osteotech shall
have the sole right to control the suit or proceeding, including the right to
conclude a settlement on terms and conditions it deems fit, provided that
Osteotech may not obligate any other Party (whether monetarily or otherwise) as
part of any such settlement without the prior written consent of such other
Party.

      11.5 Infringement of LifeNet Patents. Each Party shall advise the other
Parties promptly upon its becoming aware of any infringement by a third party of
LifeNet Patents affecting any Product in the Territory. If warranted in the
opinion of LifeNet, LifeNet shall promptly take such legal action as is required
to restrain or otherwise prevent such infringement. The other Parties shall
cooperate fully with and as requested by LifeNet, at LifeNet's expense, in
LifeNet's attempt to restrain such infringement. LifeNet shall have the sole
right to control the suit or proceeding, including the right to conclude a
settlement on terms and conditions it deems fit, provided that LifeNet may not
obligate any other Party (whether monetarily or otherwise) as part of any such
settlement without the prior written consent of such other Party.

      11.6 Technology or Intellectual Property Developed Subsequent to Effective
Date. The Parties to this Agreement acknowledge that the present Agreement is
not intended to provide for joint development of any technology or intellectual
property. Accordingly, any technology or intellectual property that any Party
develops after the Effective Date with or without funding from another Party
that relates to the Products under this Agreement shall remain the property of
the developing Party; provided that if the technology or intellectual property
could be asserted to bar the making or selling of any Products as contemplated
by this Agreement, the Party or Parties owning such technology or intellectual
property shall be deemed to have granted to the other Parties a license under
the same terms as set forth in Sections 2.4 and 2.5 to such technology or
intellectual property, solely to the extent of permitting such other Parties to
perform their obligations under this Agreement.

                                      E-59
<PAGE>

SECTION 12 DISPUTE RESOLUTION

      12.1 Mediation.

            12.1.1 Mediation by AAA. Any dispute, controversy or claim arising
out of or related to this Agreement, or the interpretation, application, breach,
termination, validity, or inducement thereof, shall, before the commencement of
any legal proceedings with respect thereto, including arbitration, first be
mediated through non-binding mediation in accordance with the Commercial
Mediation Rules promulgated by the AAA or successor thereof then in effect,
except where those rules conflict with these provisions, in which case these
provisions control. A mediation can be initiated upon any Party sending a
written notice to the other Parties stating an intent to initiate mediation. The
mediation shall be conducted in Washington, D.C. and shall be attended by a
senior executive with authority to resolve the dispute from each Party.

            12.1.2 Mediator. The mediator shall be neutral, independent,
disinterested and impartial and shall be selected from a professional mediation
firm.

            12.1.3 Selection of Mediator. The Parties shall promptly confer in
an effort to select a mediator by agreement. In the absence of such an agreement
within ten (10) calendar days after initiation of the mediation, the mediator
shall be selected by AAA in accordance with this Agreement as follows: AAA shall
provide the Parties with a list of at least fifteen (15) names. Each Party shall
exercise challenges for cause, two peremptory challenges, and rank the remaining
candidates within five (5) Business Days after receiving the AAA list. The
Parties may together interview the three top-ranked candidates for no more than
one hour each and, after the interviews, may each exercise one peremptory
challenge. The mediator shall be the remaining candidate with the highest
aggregate ranking.

            12.1.4 Mediation Procedures. The mediator shall confer with the
Parties to design procedures to conclude the mediation within no more than
forty-five (45) calendar days after initiation. Under no circumstances may the
commencement of any legal proceedings be delayed more than forty-five (45)
calendar days by the mediation process specified herein absent contrary written
agreement of the Parties.

            12.1.5 Restrictions on Parties. Each Party agrees not to use the
period or tendency of the mediation to disadvantage the other Parties
procedurally or otherwise. No statements made by either side during the
mediation may be used by the other or referred to during any subsequent
proceedings.

            12.1.6 Provisional Relief. Each Party has the right to pursue
provisional relief from any court, such as attachment, preliminary injunction,
replevin, etc., to avoid irreparable harm, maintain status quo, or preserve the
subject matter of the dispute or claim, even though mediation has not been
commenced or completed.

12.2 Arbitration.

            12.2.1 Arbitration by AAA. Any dispute, controversy or claim arising
out of or related to this Agreement, or the interpretation, application, breach,
termination, validity, or inducement thereof, that is not settled after
mediation, shall be settled by arbitration before a

                                      E-60
<PAGE>

single arbitrator in accordance with the Commercial Arbitration Rules of the AAA
then pertaining, except where those rules conflict with this provision, in which
case this provision controls. The Parties hereby consent to the jurisdiction of
the federal district court for the district in which the arbitration is held for
the enforcement of this provision and entry of judgment on any award rendered
hereunder. Should such court for any reason lack jurisdiction, any court with
jurisdiction shall enforce this clause and enter judgment on any award.

            12.2.2 Arbitrator. The arbitrator shall be an attorney who has at
least 15 years of experience with a law firm or corporate law department of over
25 lawyers or was a judge of a court of general jurisdiction for at least 10
years. The arbitrator shall be neutral, independent, disinterested, and
impartial and shall abide by The Code of Ethics for Arbitrators in Commercial
Disputes approved by the AAA.

            12.2.3 Location; Substantive Law. The arbitration shall be held in
Washington, D.C. and in rendering the award the arbitrator must apply the
internal substantive laws of the Commonwealth of Virginia, except that the
interpretation and enforcement of this arbitration provision shall be governed
by the Federal Arbitration Act.

            12.2.4 Arbitration Procedures. Within forty-five (45) calendar days
after the initiation of arbitration, the Parties shall reach agreement upon and
thereafter follow procedures assuring that the arbitration will be concluded and
the award rendered within no more than eight calendar months from the selection
of the arbitrator. Failing such agreement, the AAA will design and the Parties
will follow procedures that meet such a time schedule.

            12.2.5 Provisional Relief. Each Party has the right before, or if
the arbitrator cannot hear the matter within an acceptable period, during the
arbitration, to seek and obtain from the appropriate court provisional remedies
such as attachment, preliminary injunction, replevin, etc., to avoid irreparable
harm, maintain the status quo or preserve the subject matter of the arbitration.

            12.2.6 ARBITRATION DECISION BINDING. EACH PARTY HERETO WAIVES ITS
RIGHT TO TRIAL. THE DECISION OF THE ARBITRATOR SHALL BE BINDING UPON THE
PARTIES. THE ARBITRATOR SHALL NOT AWARD ANY PARTY PUNITIVE, SPECIAL, INCIDENTAL,
INDIRECT, CONSEQUENTIAL, EXEMPLARY OR TORT DAMAGES INCLUDING ANY DAMAGES
RESULTING FROM LOST PROFITS OR LOSS OF BUSINESS, WHETHER BASED UPON A CLAIM OR
ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR
OTHERWISE, ARISING OUT OF THIS AGREEMENT, AND EACH PARTY HEREBY WAIVES ANY RIGHT
TO SEEK SUCH DAMAGES. NO PARTY MAY SEEK OR OBTAIN PREJUDGMENT INTEREST.

SECTION 13 MISCELLANEOUS

      13.1 Notice. Any notice required or permitted hereunder to any Party shall
be given to all Parties in writing and shall be sufficiently given when
personally delivered, sent by telefax, delivered by overnight courier or mailed
by registered or certified mail, with return receipt requested, and addressed to
the Party for whom it is intended at its record address, and

                                      E-61
<PAGE>

such notice shall be effective (i) upon receipt, if delivered personally, or
(ii) upon delivery, if sent by telefax or overnight courier, or mail, provided
the sender has received written confirmation of the delivery to recipient. The
initial record addresses, telephone and facsimile numbers of the Parties are set
forth below:

         If to Osteotech:            Osteotech, Inc.
                                     51 James Way
                                     Eatontown, New Jersey  07724
                                     Attention:  President and CEO
                                     Telephone No. (732) 542-2800
                                     Facsimile No: (732) 935-0626

         if to LifeNet:              LifeNet
                                     5809 Ward Court
                                     Virginia Beach, Virginia 23455
                                     Attention:  President and CEO
                                     Telephone No. (800) 847-7831
                                     Facsimile No.: (757)464-5721

         with a copy to:             Eric A. Hauser, Esq.
                                     Williams Mullen, a Professional Corporation
                                     One Columbus Center, Suite 900
                                     Virginia Beach, VA  23462
                                     Telephone No. (757) 473-5358
                                     Facsimile No.: (757)473-0395

         if to DePuy AcroMed:        DePuy AcroMed, Inc.
                                     325 Paramount Drive
                                     Raynham, MA 02767-0350
                                     Attention:  President
                                     Telephone No.: (508) 880-8100
                                     Facsimile No.:  (508) 828-3410

         with a copy to:             DePuy AcroMed, Inc.
                                     325 Paramount Drive
                                     Raynham, MA 02767-0350
                                     Attention: Corporate Counsel
                                     Telephone No.: (508) 828-3709
                                     Facsimile No.: (508) 828-3789

         if to DePuy Orthopaedics:   DePuy Orthopaedics, Inc.
                                     700 Orthopedic Drive, P.O. Box 988
                                     Warsaw, IN 46581-0988
                                     Attention: President
                                     Telephone No.:  (574) 372-7190
                                     Facsimile No.: (574) 269-7938

                                      E-62
<PAGE>

         with a copy to:             DePuy Orthopaedics, Inc.
                                     700 Orthopedic Drive, P.O. Box 988
                                     Warsaw, IN 46581-0988
                                     Attention: Corporate Counsel
                                     Telephone No.: (574) 372-7446
                                     Facsimile No.:  (574) 372-7596

Any Party, at any time, may change its previous record address, telephone or
facsimile number by giving written notice of the substitution to the other
Parties as herein provided.

            13.2 Force Majeure. The performance by a Party of any covenant or
obligation on its part to be performed under this Agreement, with the exception
of the obligation to make any payments already due and owing to any other Party,
shall be excused by Force Majeure for so long as such Force Majeure condition
exists. The Party relying on the foregoing shall notify the other Party in
writing of the Force Majeure condition.

            13.3 Assignment. This Agreement shall be binding upon and inure to
the benefit of the Parties and their respective successors and permitted
assigns. This Agreement, or any of the rights and obligations created herein,
shall not be assigned or transferred, in whole or in part, to any Person (other
than an Affiliate of the Party proposing the assignment or transfer) by a Party
hereto without the prior written consent of the other Parties.

            13.4 Amendment. No modification or amendment hereof shall be valid
or binding upon the Parties hereto unless made in writing and duly executed by
all Parties.

            13.5 Waiver. Failure of a Party to insist upon the strict
performance of any provision hereof or to exercise any right or remedy shall not
be deemed a waiver of any right or remedy with respect to any existing or
subsequent breach or default. The waiver of any term or condition hereof must be
in writing, signed by the Party granting such waiver, and any such waiver shall
not be construed as a waiver of any other term or condition of this Agreement.

            13.6 Remedies. The remedies available to each of the Parties
pursuant to the terms of this Agreement shall be cumulative, and unless
otherwise specified herein, each Party's remedies may be exercised concurrently
or separately, and the exercise of any one remedy shall not be deemed an
election of such remedy or to preclude the exercise of any other remedy.

            13.7 Severability. In the event that any one or more of the
provisions (or any part thereof) contained in this Agreement or in any other
instrument referred to herein, shall, for any reason, be held to be invalid,
illegal or unenforceable in any respect, then to the maximum extent permitted by
law, such invalidity, illegality or unenforceability shall not affect any other
provision of this Agreement or any other such instrument. Any term or provision
of this Agreement which is invalid, illegal or unenforceable in any jurisdiction
shall, to the extent the economic benefits conferred by this Agreement to the
Parties remain substantially unimpaired, not affect the validity, legality or
enforceability of any of the terms or provisions of this Agreement in any other
jurisdiction.

            13.8 Governing Law. This Agreement shall be construed and the legal
relations between the Parties hereto determined in accordance with the laws of
the

                                      E-63
<PAGE>

Commonwealth of Virginia without regard to what laws might otherwise govern
under applicable principles of conflict or choice of law.

            13.9 Publicity. No Party shall originate any publicity, news
release, or other announcement, written or oral, whether to the public press,
the trade, its customers or otherwise, relating to this Agreement, or to
performance hereunder or the existence of an arrangement among the Parties
without providing the other Parties at least five (5) Business Days' advance
written notice of such proposed disclosure and without obtaining the other
Parties' approval of such proposed disclosure (which approval will not be
unreasonably withheld, conditioned or delayed). Neither Party shall use the name
of the other Party or any of its Affiliates for advertising or promotional
purposes without the prior written consent of such other Party (which consent
will not be unreasonably withheld, conditioned or delayed). Nothing contained in
this Section 13.9 shall prevent a Party from making a public announcement or
other public disclosure relating to this Agreement, or to performance hereunder
or the existence of an arrangement among the Parties or shall require a Party to
provide the other Parties with advance notice of or obtain the approval of the
other Parties to, any such public announcement or public disclosure to the
extent such public announcement or public disclosure is required by applicable
laws or regulations, including applicable securities laws, the rules of any
national securities exchange or quotation system upon which such Party's
securities are listed or quoted or court order. Notwithstanding the preceding
sentence, in the event that such public announcement or public disclosure is
required, the Party making the disclosure will use Reasonable Efforts to provide
a courtesy copy of any such disclosure to the other Parties twenty-four (24)
hours prior to disclosing the information publicly for the other Parties'
non-binding review and comment; provided that such requirement will not apply in
the event that the Party making the public disclosure believes in good faith
that such disclosure must be made immediately.

            13.10 Headings. The clause headings are placed herein merely as a
matter of convenience and shall not affect the construction or interpretation of
any of its provisions.

            13.11 Entire Agreement. It is the desire and intent of the Parties
to provide certainty as to their future rights and remedies against each other
by defining the extent of their undertakings herein. This Agreement and the
Primary Agreement constitute and set forth the entire agreement and
understanding among the Parties with respect to the subject matter hereof and
are intended to define the full extent of the legally enforceable undertakings
of the Parties hereto, and no promise, agreement or representation, written or
oral, which is not set forth explicitly in this Agreement or in the Primary
Agreement is intended by any Party to be legally binding. Each Party
acknowledges that in deciding to enter into this Agreement and to consummate the
transactions contemplated hereby it has not relied upon any statements, promises
or representations, written or oral, express or implied, other than those
explicitly set forth in this Agreement. This Agreement supersedes all previous
understandings, agreements and representations among the Parties, written or
oral, with respect to the subject matter hereof and thereof.

            13.12 Conflicts with Primary Agreement. In the event of a conflict
or inconsistency between the terms of this Agreement and the Primary Agreement,
the terms of this Agreement shall control.

                                      E-64
<PAGE>

            13.13 Fees and Expenses. Each Party shall pay all of its own fees
and expenses (including all legal, accounting and other advisory fees) incurred
in connection with the negotiation and execution of this Agreement and the
arrangements contemplated hereby.

            13.14 Incorporation by Reference. The Exhibits identified in this
Agreement are incorporated herein by reference and made a part hereof.

            13.15 Interpretation. The Parties have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or
question of intent or interpretation arises, this Agreement shall be construed
as if drafted jointly by the Parties and no presumption or burden of proof shall
arise favoring or disfavoring any Party by virtue of the authorship of any of
the provisions of this Agreement.

            13.16 Counterparty and Facsimile Signatures. This Agreement may be
executed in one or more counterparts, each of which when so executed and
delivered shall be deemed an original, but all of which together shall
constitute one and the same instrument. Delivery of an executed counterpart of a
signature page to this Agreement by facsimile transmission shall be effective as
delivery of a manually executed counterpart of this Agreement.

                                      E-65
<PAGE>

IN WITNESS WHEREOF, the Parties have caused this Exclusive Marketing Agreement
to be executed by their respective duly authorized officers or representatives
as of the day and year first above written.

         OSTEOTECH, INC.                        DEPUY ORTHOPAEDICS, INC.

By:      /s/ Richard W. Bauer            By:    /s/ Kevin Sidow
         -------------------------------        --------------------------------
         Name: Richard W. Bauer                 Name: Kevin Sidow
         Title: President & CEO                 Title: President

         LIFENET                                DEPUY ACROMED, INC.

By:      /s/ Richard Hurwitz             By:    /s/ Earl R. Fender
         -------------------------------        --------------------------------
         Name: Richard Hurwitz                  Name: Earl R. Fender
         Title: President/CEO                   Title: Worldwide President

                                      E-66
<PAGE>

MARKETING AGREEMENT

                                    EXHIBIT A

                                    PRODUCTS

            The following Products, as more specifically described in the table
in Section I below and containing the product specifications described in
Section II below, will be developed by Osteotech and will be subject to the
promotional arrangements of the Marketing Agreement to which this Exhibit is
attached:

I     The Products

------------------ ---------------- --------------- ----------- -------------
     PRODUCT           PRODUCT                       PACKAGE      PACKAGE
   DESCRIPTION      SPECIFICATION     TRADENAME       VOLUME     CONTAINER
------------------ ---------------- --------------- ----------- -------------
***                ***              ***             ***         ***
------------------ ---------------- --------------- ----------- -------------
***                ***              ***             ***         ***
------------------ ---------------- --------------- ----------- -------------
***                ***              ***             ***         ***
------------------ ---------------- --------------- ----------- -------------
***                ***              ***             ***         ***
------------------ ---------------- --------------- ----------- -------------

            The allograft bone tissue contained in these Products will be
processed using *** (the "REQUIRED Characteristics", with the allograft bone
tissue bearing the Required Characteristics known as the "ALLOGRAFT BONE
TISSUE"). The Required Characteristic product formulations, will be exclusive to
DePuy and LifeNet. ***

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-67
<PAGE>

MARKETING AGREEMENT

                  II.      Product Specifications

                                        *** [Two and one-half pages omitted.]

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-68
<PAGE>

MARKETING AGREEMENT

                                    EXHIBIT B

                                      ***

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-69
<PAGE>

MARKETING AGREEMENT

                                    EXHIBIT C

      OSTEOTECH SUGGESTED END USER FEES FOR THE PRODUCTS (EFFECTIVE 1/1/03)

                                       ***

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-70
<PAGE>

MARKETING AGREEMENT

                                    EXHIBIT D

                                   TRADEMARKS

OPTIUM

LIFENET

ALLOWASH(TM)

DEPUY(R)

The DePuy mark is owned by DePuy, or one of its Affiliates, and will continue to
be owned by DePuy, or one of its Affiliates.

DEPUY ACROMED(TM)

The DePuy AcroMed mark is owned by DePuy, or one of its Affiliates, and will
continue to be owned by DePuy, or one of its Affiliates.

DEPUY ACE(TM)

The DePuy ACE mark is owned by DePuy, or one of its Affiliates, and will
continue to be owned by DePuy, or one of its Affiliates.

OSTEOTECH(TM)

The Osteotech mark is owned by Osteotech and will continue to be owned by
Osteotech.

OSTEOTECH LOGO

[GRAPHIC OMITTED]

The Osteotech logo is owned by Osteotech and will continue to be owned by
Osteotech.

                                      E-71
<PAGE>

Marketing Agreement

                                    EXHIBIT E

                               PROMOTIONAL BUDGET

                                       ***

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-72
<PAGE>

MARKETING AGREEMENT

                                    EXHIBIT F

                               OSTEOTECH PATENTS

                                    OSTEOTECH
                            LIST OF RELEVANT PATENTS

<TABLE>
<CAPTION>
--------------- ---------------------------------------------------------------------------------------------- ---------------
ISSUED          PATENT TITLE                                                                                   ISSUE DATE
PATENT
NUMBER
--------------- ---------------------------------------------------------------------------------------------- ---------------
<S>             <C>                                                                                            <C>
                ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------

--------------- ---------------------------------------------------------------------------------------------- ---------------
                ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------

--------------- ---------------------------------------------------------------------------------------------- ---------------
                ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
                ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
***             ***                                                                                            ***
--------------- ---------------------------------------------------------------------------------------------- ---------------
</TABLE>

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-73
<PAGE>

MARKETING AGREEMENT

                                    EXHIBIT G

                           LIFENET TECHNOLOGY PATENTS

                        LIFENET LIST OF RELEVANT PATENTS

        ***

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-74
<PAGE>

MARKETING AGREEMENT

                                    EXHIBIT H

                         FINAL PACKAGING SPECIFICATIONS

        ***

----------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-75
<PAGE>

                                    EXHIBIT I

        ***

--------
***  Indicates the omission of confidential material pursuant to the request for
     confidential treatment made in accordance with Rule 24b-2 under the
     Securities Exchange Act of 1934, as amended. The confidential material is
     being filed separately with the Securities and Exchange Commission.

                                      E-76Exhibit 10.39

Richard W. Bauer
President and CEO
Osteotech, Inc.
51 Jamesway
Eatontown, NJ  07724                                            October 27, 2002

American Red Cross-Tissue Services
National Headquarters
Attn: Henry Korent, Chief Executive Officer
1621 North Kent St.
Arlington, VA 22209

Re: Letter agreement to amend, modify and restate certain provisions of the
    processing agreement (the "Amendment")

Ladies and Gentlemen:

Reference is made herein to that certain Agreement dated December 10, 1996 by
and between the American Red Cross, operating through the Tissue Services unit
of its Biomedical Services division ("ARC"), and Osteotech, Inc. ("Osteotech"),
as amended (the "Agreement"). Unless otherwise defined herein, initially
capitalized terms used herein shall have the meaning ascribed to them in the
Agreement.

Pursuant to Section 13 of the Agreement, we submit this letter to you for your
review and consent to the following amended and restated provisions which shall
apply in full force and effect until the earlier of (i) the expiration or
termination of the Agreement, or (ii) the execution of a new definitive
processing agreement between ARC and Osteotech:

      1.    The following terms used in this Amendment shall have the following
            definitions:

      (a) "Donor" shall mean a Standard Donor or Non-Standard Donor from whom
      Tissue is to be (or has been) procured and

                                      E-77
<PAGE>

Richard W. Bauer
October 27, 2002
Page 2

      delivered by ARC in accordance with the provisions of this Agreement.

      (b) "Proprietary Products" shall mean those products which exist as of the
      date of this Amendment, are processed by Osteotech from Tissue and are
      covered by patents owned or licensed by Osteotech or are otherwise
      produced by Osteotech using its trade secrets or other proprietary
      information. For purposes of this Agreement, the Proprietary Products in
      existence as of the date of this Amendment are all forms of Osteotech's
      Grafton(R) DBM, Grafton Plus(TM) and Graftech(TM) Bioimplant products.
      Additional Proprietary Products may be added to the Agreement from time to
      time upon the mutual agreement of Osteotech and ARC.

      (c) "Standard Donor" shall mean: (i) a human male not less than *** years
      of age and not greater than *** years of age at date of death; or (ii) a
      human female not less than *** years of age and not greater than *** years
      of age at date of death. "Non-Standard Donor" shall mean: (i) a human male
      not less than *** years of age and not greater than *** years of age at
      date of death; or (ii) a human female not less than *** years of age and
      not greater than *** years of age at date of death.

2.    The third recital following the introductory paragraph of the Agreement
      shall be amended and restated in its entirety to read as follows:

      "WHEREAS, ARC wishes to ensure its ability to obtain processing services
      as well as distribution, education and marketing and, from time to time,
      other services and Osteotech desires to perform such services and to
      process Tissue for ARC."

*** Indicates the omission of confidential material pursuant to a request for
confidential treatment made in accordance with Rule 24b-2 under the Securities
Exchange Act of 1934, as amended. The confidential material is being filed
separately with the Secretary to the Securities and Exchange Commission.

                                      E-78
<PAGE>

Richard W. Bauer
October 27, 2002
Page 3

      3. Section 1.1.1 shall be amended and restated in its entirety to read as
      follows:

      "(a) Commencing as of January 1, 2003 and through the remaining term of
      the Agreement, ARC shall not be required to supply all of the Tissue that
      it procures to Osteotech for Processing, but will instead exercise its
      best efforts to provide to Osteotech for Processing no less than the
      minimum number of Standard Donors and Non-Standard Donors set forth below
      during each month of the time periods set forth below (the "Minimum Donor
      Requirement")".

                                              MONTHLY MINIMUM NUMBER
                                              ----------------------
       TIME PERIOD                  STANDARD DONORS          NON-STANDARD DONORS
       -----------                  ---------------          -------------------
 1/1/03 through 12/31/03                  ***                        ***
 1/1/04 through 12/31/04                  ***                        ***
 1/1/05 through 12/31/05                  ***                        ***
 1/1/06 through 12/31/06                  ***                        ***

      (b) No later than the fifteenth (15th) business day of each of January
      2003, 2004, 2005 and 2006 an authorized officer of ARC shall deliver to
      Osteotech a certification of the Average Donor Profile (as defined below)
      of all of the Standard Donors and all of the Non-Standard Donors (as
      independent groups) procured by ARC during the immediately preceding
      calendar year, provided that the Average Donor Profile to be delivered in
      January 2003 shall be based upon the Donors delivered by ARC to Osteotech
      during the twelve (12) months ended August 31, 2002. The "Average Donor
      Profile" shall mean that certain description of the average number and
      types of Tissue procured, the average age of the Donors and the male to
      female ratio of the Donors procured by ARC.

*** Indicates the omission of confidential material pursuant to a request for
confidential treatment made in accordance with Rule 24b-2 under the Securities
Exchange Act of 1934, as amended. The confidential material is being filed
separately with the Secretary to the Securities and Exchange Commission.

                                      E-79
<PAGE>

Richard W. Bauer
October 27, 2002
Page 4

                  The Donors delivered by ARC to Osteotech during each of the
                  remaining years of the Agreement in order to satisfy the
                  Minimum Donor Requirement shall conform to the Average Donor
                  Profile delivered by ARC to Osteotech during the January of
                  that year. Osteotech shall receive all of the Tissue procured
                  from each Donor that is delivered by ARC to Osteotech in order
                  to satisfy the Minimum Donor Requirement and ARC shall use its
                  best efforts to ensure that the Donors it delivers to
                  Osteotech shall come proportionally from geographic regions
                  which are consistent with the proportion of releasable Donors
                  procured in geographic regions ARC procures Donors from.

                  (c) Notwithstanding anything to the contrary contained in the
                  Agreement, for the year commencing January 1, 2003, ARC shall
                  be responsible for planning Donors for Processing that are
                  delivered by ARC to Osteotech and shall plan such Donors in a
                  manner and method (which is generally understood to be the
                  Donor master production plan) which is consistent with the
                  manner in which ARC planned Donors it delivered to Osteotech
                  during 2002. Notwithstanding anything to the contrary
                  contained in the Agreement, commencing January 1, 2004 and for
                  the remaining term of the Agreement, Osteotech shall be
                  responsible for planning Donors for Processing that are
                  delivered by ARC to Osteotech in order to satisfy the Minimum
                  Donor Requirement, as needed to produce Proprietary Products.
                  Such planning shall be based upon Osteotech's forecasted
                  market needs solely with respect to Donors delivered in
                  accordance with the Minimum Donor Requirement, and such plans
                  shall be provided to ARC in good faith and on a quarterly
                  basis thirty (30) days prior to the quarter in which such
                  forecast shall apply. ARC acknowledges that such planning by
                  Osteotech shall be prepared with a priority on meeting the
                  forecasted market demand of Proprietary Products first, with
                  base Tissue products or non-proprietary products a secondary
                  consideration. Unless and until another agreement is mutually
                  agreed to between the parties, once the Minimum Donor
                  Requirement threshold is satisfied, for each Donor that is
                  delivered to Osteotech that exceeds such requirement,
                  Osteotech shall use its best efforts to follow the Donor
                  master production plan submitted by ARC with respect to any
                  such Donor(s) with the goal of prioritizing its efforts so
                  that such Donors shall be processed into

                                      E-80
<PAGE>

Richard W. Bauer
October 27, 2002
Page 5

                  base Tissue or non-proprietary products first, and Proprietary
                  Products second; and provided, further that the average yield
                  of Tissue products processed from such Donors in each of the
                  years 2003, 2004, 2005 and 2006 shall not differ from the
                  average yield of the same received by ARC during the
                  immediately preceding year (except that for 2003 the required
                  yield shall be based on the 12 months ended August 31, 2002),
                  provided, further, that such Donors comply with the Average
                  Donor Profile for the immediately preceding year (except that
                  for 2003 the Average Donor Profile shall be based on the 12
                  months ended August 31, 2002).

                  (d) Osteotech shall use its best efforts to process the soft
                  Tissue associated with any and all Donors delivered to
                  Osteotech in accordance with specifications for such soft
                  Tissue that are in place as of the date of this Amendment
                  based upon the donor master production plan submitted by ARC
                  to Osteotech. In the event any such specifications are changed
                  in a manner which would cause Osteotech to incur additional
                  processing expenses that are reasonably considered to be
                  material, Osteotech will not be required to process soft
                  Tissue in accordance with such changed specifications unless
                  ARC shall reimburse Osteotech for such additional processing
                  expenses, plus a reasonable profit.

                  (e) ARC may, at its option, deliver to Osteotech for
                  Processing more Standard Donors or more Non-Standard Donors
                  than it is required to deliver to meet the Minimum Donor
                  Requirement, provided that commencing as of January 1, 2003
                  and for the remaining term of the Agreement, the number of
                  such additional Non-Standard Donors delivered in any month
                  shall not exceed *** of the number of Non-Standard Donors
                  required to be delivered in such month in order to satisfy the
                  Minimum Donor Requirement for Non-Standard Donors in such
                  month.

*** Indicates the omission of confidential material pursuant to a request for
confidential treatment made in accordance with Rule 24b-2 under the Securities
Exchange Act of 1934, as amended. The confidential material is being filed
separately with the Secretary to the Securities and Exchange Commission.

                                      E-81
<PAGE>

Richard W. Bauer
October 27, 2002
Page 6

                  Notwithstanding anything to the contrary contained herein, the
                  number of Donors required to be delivered by ARC to Osteotech
                  in order to satisfy the Minimum Donor Requirement in any month
                  may be reduced in the event an authorized officer of ARC
                  provides a written certification to Osteotech that ARC was
                  unable to procure the number of Donors required to be
                  delivered to Osteotech in such month in order to satisfy the
                  Minimum Donor Requirement for such month. Such certification
                  must be delivered no later than the end of the third month
                  after any such shortfall in Donors shall occur and shall
                  certify (i) that the number of Donors available for Processing
                  was insufficient to satisfy the Minimum Donor Requirement for
                  such month, (ii) that the ratio of the number of Donors being
                  provided to Osteotech for Processing compared to the total
                  number of donors procured by ARC is no less than the ratio of
                  Donors provided to Osteotech for Processing compared to the
                  total number of donors procured by ARC during the preceding
                  six (6) months and (iii) the reasons why ARC was unable to
                  procure a number of Donors sufficient to satisfy the Minimum
                  Donor Requirement. In addition, in the event ARC is unable to
                  satisfy the Minimum Donor Requirement as a result of Osteotech
                  or any of Osteotech's affiliates, as defined in the Securities
                  Exchange Act of 1934, as amended, (but not including any
                  processing customer of Osteotech) obtaining Donors directly
                  from any of ARC's donor accounts existing as of the date of
                  this Amendment as set forth in a letter which will be provided
                  by ARC to Osteotech within 30 days after the date of this
                  Agreement (the "Existing Account Letter"), the number of
                  Donors required to be delivered by ARC each month in order to
                  satisfy the Minimum Donor Requirement shall be reduced by the
                  number of Donors procured by Osteotech from any such existing
                  donor account(s) during such month. Within 30 days of its
                  receipt of the Existing Account Letter Osteotech shall advise
                  ARC in writing of those accounts on the Existing Account
                  Letter with which Osteotech has an existing arrangement to
                  receive donors. Within 30 days of its receipt of such written
                  notice from Osteotech, ARC shall revise the Existing Account
                  Letter to set forth the minimum monthly or annual, as the case
                  may be, number of donors ARC is entitled to receive, from such
                  accounts with which Osteotech has an existing relationship, in
                  accordance with any contract ARC may have with such accounts.
                  If ARC's contract with any of the accounts listed

                                      E-82
<PAGE>

Richard W. Bauer
October 27, 2002
Page 7

                  on the Existing Account Letter shall terminate and not be
                  renewed, ARC shall so advise Osteotech in writing and such
                  account shall be removed from the Existing Account Letter.
                  Osteotech shall have the right to audit ARC's donor
                  procurement activities to determine the accuracy of any such
                  certification provided to it by ARC. The Existing Account
                  Letter shall be treated as Confidential Information under the
                  Agreement.

                  (g) ARC shall pay Osteotech the Processing fees set forth in
                  Exhibits 3.1, and 3.2 of the Agreement and all applicable
                  pricing amendments to the Agreement with respect to all Donors
                  delivered by ARC to Osteotech and Processed by Osteotech and
                  for all Proprietary Products Processed from Donors delivered
                  by ARC to Osteotech. The fee payable for "Base Donor Charge (7
                  or greater tissues)" on Exhibit 3.1 shall be the fee payable
                  for Processing Standard Donors and the fee payable for
                  "Exception Donor Charge" on Exhibit 3.1 shall be the fee
                  payable for Processing Non-Standard Donors. If any new
                  Proprietary Products are added to the Agreement the Processing
                  fees for such products will be agreed upon by the parties. ***
                  Notwithstanding anything to the contrary contained in this
                  Amendment or the Agreement, including without limitation,
                  Exhibit 3.1 thereof, as amended, Osteotech shall be entitled
                  to increase the base Tissue Processing fees set forth in
                  Exhibit 3.1, as amended, charged to ARC by up to *** on each
                  of January 1, 2003, 2004, 2005 and 2006 and notes 1, 2 and 3
                  of Exhibit 3.1 are hereby deleted.

*** Indicates the omission of confidential material pursuant to a request for
confidential treatment made in accordance with Rule 24b-2 under the Securities
Exchange Act of 1934, as amended. The confidential material is being filed
separately with the Secretary to the Securities and Exchange Commission.

                                      E-83
<PAGE>

Richard W. Bauer
October 27, 2002
Page 8

                  (h) The Donors shall be delivered to Osteotech, at ARC's
                  expense. The Tissue from such Donors delivered by ARC and
                  processed by Osteotech shall conform to all standards,
                  guidelines, rules, regulations and laws of (i) the United
                  States Food and Drug Administration (FDA); (ii) the American
                  Association of Tissue Banks (AATB); (iii) other applicable
                  U.S. federal, state and local government agencies; (iv) any
                  non-U.S. jurisdiction where Tissue may be procured or
                  distributed for purposes of this Agreement; (v) ARC's standard
                  operating procedures ("SOPs") as may be amended from time to
                  time by ARC; (vi) Osteotech's processing standards as
                  specified in Osteotech's SOPs, as may be amended from time to
                  time by Osteotech (collectively, the foregoing is hereinafter
                  referred to as the "Processing Standards"). If interpretation
                  of the Processing Standards is required, or if there is a
                  disagreement about the interpretation of the Processing
                  Standards, ARC and Osteotech will enter into good faith
                  negotiations to resolve such issues with thirty (30) days of
                  notice by one party to the other. If such issues are not
                  resolved within the thirty (30) day period, within five (5)
                  business days thereafter, an independent third party will be
                  mutually selected from a list of six (6) with three (3)
                  provided by ARC and three (3) provided by Osteotech and such
                  third party will assist the parties in arriving at a
                  resolution. In the event no resolution is reached within sixty
                  (60) days after such third party is appointed, either party
                  may seek relief from the courts or as otherwise mutually
                  agreed. "Recovery Standards" shall mean all applicable laws,
                  standards, rules, regulations, procedures and guidelines
                  related to the donation, recovery and suitability
                  determination of Tissue, including donor referral, informed
                  consent, tissue recovery, pre-processing storage, packaging
                  and shipping and all records, activities and standards related
                  to obtaining, testing, documenting and evaluating serological
                  test results, medical history and lifestyle data; and related
                  organizational, management and quality assurance activities.

                  (i) ARC and Osteotech shall provide each other a copy of its
                  SOPs and copies of any amendments to its SOPs promptly after
                  such amendments are adopted; provided, however, that doing so
                  will not require such party to disclose any trade secrets,
                  technical know how or unpublished scientific data or technical
                  art. Upon reasonable notice and at its own expense, each of
                  Osteotech and ARC shall have the right to conduct an annual
                  audit of the other party's facilities and records related to
                  regulatory compliance. Upon

                                      E-84
<PAGE>

Richard W. Bauer
October 27, 2002
Page 9

                  reasonable notice and at its own expense, each of Osteotech
                  and ARC shall have the right to conduct additional audits of
                  the other party's facilities and records related to regulatory
                  compliance in the event there are repeated significant defects
                  in such other party's SOPs, or in such other party's
                  compliance with its SOPs or any applicable Processing
                  Standards."

                  ARC shall reimburse Osteotech on a monthly basis for all of
                  Osteotech's direct costs, including without limitation, rent
                  and utilities, related to the use of Osteotech's facilities by
                  ARC personnel.

         3.       With regard to Section 1.1.2(c) we hereby agree to strike and
                  delete the following sentence which is the last sentence of
                  such subsection so that it shall have no further force or
                  effect:

                  "If the parties cannot agree upon a forecast for any month,
                  the forecast for such month shall be the average of the
                  forecasts of the parties for the immediately preceding three
                  months."

         4.       With regard to Section 1.1.3 we hereby agree to strike and
                  delete the following two sentences which are the last two
                  sentences of the first paragraph of Section 1.1.3 so that it
                  shall have no further force or effect:

                  "ARC shall provide to Osteotech, within 15 days of the end of
                  each calendar quarter, data on the tissue procurement activity
                  of ARC occurring during the quarter. Osteotech shall have the
                  right to audit ARC Tissue donor data upon reasonable prior
                  written notice to ARC."

         5.       With regard to Section 1.2.2(b) we hereby agree that the
                  second sentence of Section 1.2.2(b) shall be amended and
                  restated in its entirety as follows:

                  "In the event either party is unable or unwilling to implement
                  such changes, the other party shall have the remedy set forth
                  in Section 6.5"

         6.       With regard to Section 3.1(c) we hereby agree to strike and
                  delete the entire provision so that it shall have no further
                  force or effect.

                                      E-85
<PAGE>

Richard W. Bauer
October 27, 2002
Page 10

            7.    With regard to Section 6.5 we hereby agree that the following
                  shall be added to the end of Section 6.5:

                  "and Osteotech may terminate this Agreement at any time upon
                  30 days prior written notice to ARC if ARC is unwilling or
                  unable to comply with the provisions of Section 1.2.2(b)."

            8.    Section 8 shall be amended and restated in its entirety to
                  read as follows:

                  Neither party shall be responsible to the other for
                  nonperformance or delayed performance of the terms and
                  conditions hereof due to acts of God, acts of government,
                  wars, riots, major accidents involving lines of
                  transportation, fuel or material shortages, or other causes
                  (except strikes), in the nature of force majeure which is
                  beyond the affected party's control. Notwithstanding such
                  force majeure event, to the extent Osteotech is unable to
                  perform Processing of ARC's Tissue due to a force majeure
                  event for more than *** successive *** or *** in the aggregate
                  during any *** period, Osteotech may arrange, with ARC's
                  approval, or in the alternative, ARC may arrange, for ARC's
                  base Tissue to be processed by another processor within *** of
                  such event. In no event shall ARC have the right to cause any
                  Proprietary Product to be processed by any other processor.

*** Indicates the omission of confidential material pursuant to a request for
confidential treatment made in accordance with Rule 24b-2 under the Securities
Exchange Act of 1934, as amended. The confidential material is being filed
separately with the Secretary to the Securities and Exchange Commission.

                                      E-86
<PAGE>

Richard W. Bauer
October 27, 2002
Page 11

                  Once notice is given that the force majeure event has ended
                  all base Tissue Processing which is being performed by any
                  other processor as a result of such force majeure event shall
                  promptly revert back to Osteotech for Processing; provided
                  that, ARC may require Osteotech to reimburse ARC for the
                  difference between the Processing Fees, shipping and packaging
                  costs that would have been payable by ARC to Osteotech under
                  the Agreement for Tissue processed by such other processor and
                  the actual costs incurred by ARC to obtain substantially
                  similar services from an alternate processor, provided further
                  that Osteotech shall in no event be responsible to pay to ARC
                  an amount which is in excess of *** of such fees and costs in
                  the aggregate that would have otherwise been payable to
                  Osteotech by ARC

The Agreement shall continue in full force and effect in accordance with its
terms except as specifically amended in this Amendment. To the extent you are in
agreement with the foregoing amendments and modifications to the Agreement,
please acknowledge your consent by signing in the signature block provided
below. This Amendment may be signed in one or more counterparts, each of which
shall be deemed an original, but all of such counterparts when brought together
shall constitute one Amendment and agreement to the same.

Sincerely,                             ACKNOWLEDGED AND AGREED:

Osteotech, Inc.                        American Red Cross-Tissue Services

By:  _____________________             By:  ___________________________
        Richard W. Bauer                       Henry Korent
        President and Chief Executive          Chief Executive Officer
        Officer

*** Indicates the omission of confidential material pursuant to a request for
confidential treatment made in accordance with Rule 24b-2 under the Securities
Exchange Act of 1934, as amended. The confidential material is being filed
separately with the Secretary to the Securities and Exchange Commission.

                                      E-87

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}]]